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 ABSTRACT 
 
Over the past two decades the U.S. Environmental Protection Agency (EPA) has issued a 
series of Federal guidance documents for the purpose of providing the Federal and State agencies 
with technical information to assist their implementation of radiation protection programs.  
Currently recommended dose conversion factors, annual limits on intake, and derived air 
concentrations for intake of radionuclides are tabulated in Federal Guidance Report No. 11 
(FGR 11), published in 1988. The tabulations in FGR 11 were based on dosimetric quantities 
and biokinetic and dosimetric models of the International Commission on Radiological 
Protection (ICRP) developed for application to occupational exposures.  Since the publication of 
FGR 11 the ICRP has revised some of its dosimetric quantities and its models for workers and 
has also developed age-specific models and dose conversion factors for intake of radionuclides 
by members of the public.  This report examines the extent of the changes in the inhalation and 
ingestion dose coefficients of FGR 11 implied by the updated recommendations of the ICRP, 
both for workers and members of the public. 
 xv
 
 xvi
 
1.  INTRODUCTION 
 
Over the past two decades the U.S. Environmental Protection Agency (EPA) has issued a 
series of Federal guidance documents for the purpose of providing the Federal and State agencies 
with technical information to assist their implementation of radiation protection programs.  
Currently recommended dose conversion factors and corresponding annual limits on intake 
(ALIs) and derived air concentrations (DACs) for intake of radionuclides are tabulated in 
Federal Guidance Report No. 11 (EPA, 1988).  The tabulations were based on the radiation 
protection guidance given in two reports by the International Commission on Radiological 
Protection (ICRP) that have since been superseded:  ICRP Publication 26 (1977), which defined 
the dosimetric quantities and dose limitation system and provided primary guidance for assessing 
radiation dose to workers; and ICRP Publication 30 (1979, 1980, 1981, 1988a), which 
recommended biokinetic and dosimetric models and provided secondary guidance in the form of 
limits on intake for workers. The guidance and models underlying Federal Guidance Report 
No. 11 were designed for application to occupational exposures to radionuclides but have been 
applied to environmental exposures as well. 
The dosimetric quantities and primary guidance of ICRP Publication 26 (1977) were 
superseded by ICRP Publication 60 (1991).  The concept of effective dose as defined in 
Publication 60 differs little from that originally formulated in Publication 26, but Publication 60 
revised and extended the list of tissue weighting factors used to calculate effective dose 
coefficients. 
The guidance on occupational exposure to radionuclides given in ICRP Publication 30 
was superseded by ICRP Publication 68 (1994a).  The dosimetric models and methods used in 
ICRP Publication 68 do not differ greatly from those used in ICRP Publication 30, but many of 
the systemic biokinetic models and reference gastrointestinal absorption fractions (f1 values) 
were changed substantially.  Systemic biokinetic models carried over from ICRP Publication 30 
generally had to be modified for use in Publication 68 because they did not explicitly address 
some tissues that were given weighting factors in ICRP Publication 60 (1991) but not in 
Publication 26 (1977).  In particular, loss of activity from the body in excretion was depicted 
explicitly in the biokinetic models of Publication 68 in order to address the doses to the colon 
and urinary bladder. 
A particularly important difference between ICRP Publication 30 and Publication 68 is 
the application of substantially different models of the respiratory tract.  The updated respiratory 
model used in Publication 68 was introduced in ICRP Publication 66 (1994b).  That model 
involves greater detail and physiological realism than the respiratory model used in Publication 
30 and produces considerably different predictions for some situations. 
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Several of the biokinetic models and f1 values used in ICRP Publication 68 were taken 
from a series of ICRP documents, initiated in the late 1980s, on doses to members of the public 
from intake of radionuclides (ICRP 1989, 1993, 1995a, 1995b, 1996).  Those documents provide 
age-specific dosimetric and biokinetic models, including gastrointestinal uptake fractions, for 31 
environmentally important elements.  With the exception of gastrointestinal uptake fractions for 
a few elements, the models for the adult given in those documents were considered appropriate 
for application to workers and were used in Publication 68. 
The purpose of this report is to examine the extent of the changes in the inhalation and 
ingestion dose coefficients of Federal Guidance Report No. 11 implied by the updated 
recommendations of the ICRP, both for workers and members of the public.  Specifically, the 
dose coefficients given in Federal Guidance Report No. 11 are compared with: (1) values for the 
worker produced by the models and assumptions of ICRP Publication 68 (1994a), and (2) values 
for members of the public generated by the models and assumptions used in the ICRP’s series of 
documents on environmental intakes. 
The report is divided into five parts.  Section 2 describes the changes that have been 
made since the appearance of ICRP Publication 30 in the effective dose concept and tissue 
weighting factors and examines the sensitivity of effective dose coefficients to these changes.  In 
Section 3 the ICRP’s updated respiratory model is described, and its structure and predictions are 
compared with the respiratory model used in ICRP Publication 30.  Sections 4 and 5 discuss 
changes in the ICRP’s gastrointestinal absorption fractions and systemic biokinetic models, 
respectively, and examine implications of those changes.  Section 6 examines the net effects, 
with regard to derived dose coefficients, of the updated models discussed in Sections 2-5. 
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 2.   REVISION OF TISSUE WEIGHTING FACTORS 
 
 2.1.  Comparison of previous and updated tissue weighting factors 
The effective dose equivalent, HE, defined in ICRP Publication 26 (1977) is a weighted 
sum of doses to selected tissues.  It is defined as 
 HE  = Σ wT HT 
 T 
 
where wT is a weighting factor for tissue T and HT is the mean dose equivalent to that tissue.  
Because the weighting factors are normalized to sum to 1.0, a weighting factor for tissue T 
corresponds to the fractional contribution of that tissue to the total risk of stochastic health 
effects when the body is uniformly irradiated.  The weighting factors given in ICRP 
Publication 26 and used in ICRP Publication 30 (1979, 1980, 1981, 1988a) and Federal 
Guidance Report No. 11 are shown in Table 2.1. 
ICRP Publication 26 (1977) was superseded by Publication 60 (1991), which introduced 
a new dosimetric quantity called the effective dose, E.  The effective dose is also a weighted sum 
of doses to radiosensitive tissues: 
   E  = Σ wT HT 
 T 
 
In contrast to the definition of the effective dose equivalent HE, the weighting factors wT in the 
equation for the effective dose E are not specified as part of the definition of E but can take any 
assigned values.  Thus, the effective dose equivalent, HE, may be interpreted as a special case of 
the effective dose, E.  In the following, lower case e will be used to denote an effective dose 
coefficient for intake of a radionuclide through inhalation or ingestion. 
Values recommended in ICRP Publication 60 for the tissue weighting factors wT are also 
shown in Table 2.1.  This list of tissue weighting factors reflects updated information on tissues 
at risk as well as risk per unit dose and includes values for the following tissues not addressed 
explicitly in ICRP Publication 26:  colon, stomach, urinary bladder wall, liver, esophagus, and 
skin. The largest changes to existing tissue weighting factors were a threefold reduction for bone 
surface, a 67% increase for the thyroid, and a sixfold reduction of the weight to remaining tissues 
in conjunction with a reduction in the number of radiosensitive tissues that were not assigned a 
specific factor. 
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Table 2.1.  Tissue weighting factors given in ICRP Publication 26 
(1977) and ICRP Publication 60 (1991)a. 
 
 
 
 
Tissue weighting factor (wT) 
 
Organ or tissue 
 
ICRP Pub.  26 
 
ICRP Pub.  60 
 
Gonads 
 
0.25 
 
0.20 
 
Bone marrow (red) 
 
0.12 
 
0.12 
 
Colon 
 
-- 
 
0.12 
 
Lung 
 
0.12 
 
0.12 
 
Stomach 
 
-- 
 
0.12 
 
Bladder 
 
-- 
 
0.05 
 
Breast 
 
0.15 
 
0.05 
 
Liver 
 
-- 
 
0.05 
 
Esophagus 
 
-- 
 
0.05 
 
Thyroid 
 
0.03 
 
0.05 
 
Skin 
 
-- 
 
0.01 
 
Bone surface 
 
0.03 
 
0.01 
 
Remainder 
 
0.30a 
 
0.05b,c 
 
aThe value 0.30 is applied to the average dose to the five remaining 
tissues receiving the highest dose, excluding the skin, lens of the eye, and 
the extremities. 
bRemainder is composed of the following tissues: adrenals, brain, 
extrathoracic airways, small intestine, kidneys, muscle, pancreas, spleen, 
thymus, and uterus. 
cThe value 0.05 is applied to the mass-weighted average dose to the 
Remainder tissue group, except when the following “splitting rule” 
applies: If a tissue of Remainder receives a dose in excess of that 
received by any of the 12 tissues for which weighting factors are 
specified, a weighting factor of 0.025 (half of Remainder) is applied to 
that tissue and 0.025 to the mass-averaged committed equivalent dose in 
the rest of the Remainder tissues. 
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2.2.  Sensitivity of effective dose coefficients for workers to updated weighting factors 
For a given radionuclide and intake mode, the sensitivity of dose coefficients to changes 
in tissue weighting factors depends on the biokinetic models applied.  Two separate sensitivity 
analyses were performed, one based on the biokinetic models of ICRP Publication 30 and the 
other based on the ICRP’s updated models.  In the following, an effective dose coefficient based 
on tissue weighting factors of ICRP Publication 26 (1977) is denoted e(26) and a coefficient 
based on weighting factors of ICRP Publication 60 (1991) is denoted e(60). 
 
2.2. 1. Sensitivity analysis based on models of ICRP Publication 30 
The analysis based on the biokinetic models of ICRP Publication 30 indicates that 
effective dose coefficients for most radionuclides are relatively insensitive to the changes in the 
tissue weighting factors.  The values e(60) and e(26) are virtually identical for cases in which the 
integrated dose is nearly uniformly distributed among tissues.  This is because the weighting 
factors sum to 1.0 in each case, and the expression for the effective dose is almost numerically 
equivalent to the average of the integrated doses to the various tissues. 
Cases for which changes in tissue weighting factors led to a change of 40% or more in 
the effective dose coefficient are listed in Table 2.2 (inhalation) and Table 2.3 (ingestion).  As 
indicated in the last column of each of these tables, differences of this magnitude are usually 
associated with one or more of the following factors: 
1.  A threefold reduction of the weighting factor for bone surface, which results in a two- 
to threefold decrease in effective dose coefficients for some bone-seeking radionuclides. 
2.  A 67% increase in the weighting factor for thyroid.  For example, this leads to 
noticeable increases (up to 67%) in the effective dose coefficients for inhalation of some 
isotopes of tellurium and iodine in soluble or moderately soluble form (Class D or W). 
3.  Introduction of explicit weighting factors for colon and stomach.  This is particularly 
important for consideration of some short-lived radionuclides but affects effective dose 
estimates for some important long-lived radionuclides as well. 
4. A decrease in the weight of Remainder, which affects the contribution of tissues such 
as the kidneys that are not named explicitly in either set of weighting factors. 
 
For inhalation, the largest changes in the effective dose coefficients generally are for 
soluble or moderately soluble forms of radionuclides.  For inhalation of a radionuclide in 
relatively insoluble form, there is usually little difference between E and HE derived from the 
same biokinetic models because both values typically are dominated by the dose to the lung, 
whose weighting factor (0.12) was not changed in ICRP Publication 60. 
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Table 2.2.   Inhalation cases most affected by revision of tissue weighting factors (ICRP, 
1991), based on biokinetic and dosimetric models of ICRP Publication 30.  The cases listed 
are those for which the effective dose coefficients are changed by more than 40% when 
weighting factors of ICRP Publication 26 are replaced by those of ICRP Publication 60.  
 
 
Radionuclides 
 
Class 
 
e(60):e(26) 
 
Modification(s) of weighting factors 
having greatest influence on 
effective dose coefficient 
 
Zr-93, Te-123m, Te-123, Gd-148, 
Gd-152, Hf-182, Pb-210 
 
D 
 
~0.5-0.6 
 
Threefold reduction of factor for bone surface. 
The number of radionuclides in this set is 
limited by the fact that Class D was not 
considered in ICRP Pub. 30 for many 
bone-seeking radionuclides such as the 
actinides and lanthanides. 
 
Zr-93, Te-123, Gd-148, Gd-152, Lu-176, 
Hf-182, Th-228, Th-229, Th-230, 
Th-232, Pa-231, Pa-232, Np-232, 
Np-236a, Np-236b, Np-237, Np-238, 
Pu-238, Pu-239, Pu-240, Pu-241, 
Pu-242, Pu-244, Am-241, Am-242m, 
Am-243, Cm-245, Cm-246, Cm-247, 
Cm-248, Cm-250, Bk-247, Bk-249, 
Bk-250, Cf-249, Cf-250, Cf-251, Es-250 
 
W 
 
~0.5-0.6 
 
Threefold reduction of factor for bone surface. 
For many of these bone-seeking 
radionuclides, the decrease due to the 
reduced weighting factor for bone was partially 
offset by other changes, such as introduction 
of a weighting factor for liver. 
 
U-230, U-232, U-233, U-234, U-235, 
U-236, U-238 
 
D 
 
~0.3-0.4 
 
Threefold reduction of factor for bone surface 
and reduction of contribution of kidney dose to 
Remainder. The latter arises due to reduction 
of weighting factor for Remainder and 
introduction of mass weighting for doses. 
 
Tc-97m, Tc-97, Tc-99, Re-184m, 
Re-186m, Re-186, Re-187, Re-188m, 
Re-188, Re-189 
 
D 
 
~1.4-1.7 
 
Introduction of a weighting factor for stomach 
wall (source organ in biokinetic models for Tc 
and Re.  The portion of total-body decays 
occurring in the stomach is relatively high for 
some inhaled short-lived radionuclides. 
 
Te-131m, Te-132, Te-133m, Te-133, 
I-121, I-123, I-124, I-125, I-126, I-129, 
I-130, I-131, I-132m, I-133, I-135 
 
D 
 
~1.4-1.7 
 
Increase in weighting factor for thyroid, which 
dominates effective dose for these cases. 
 
Te-131m, Te-131, Te-132, Te-133m, 
Te-133 
 
W 
 
~1.4-1.5 
 
Increase in weighting factor for thyroid, which 
dominates effective dose for these cases. 
 
Cd-109, Cd-133m, Cd-113, Cd-115, 
Bi-210m, Bi-210, Po-210 
 
D 
 
~0.4-0.5 
 
HE is dominated by tissues in Remainder 
(kidney for Bi and Cd and spleen plus kidney 
for Po) that contribute little to E because of 
their small masses. 
 
Cd-113m, Cd-113 
 
W 
 
~0.5 
 
HE is dominated by a tissue in Remainder 
(kidney) that contributes little to E because of 
its small mass. 
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Table 2.3.   Ingestion cases most affected by revision of tissue weighting factors (ICRP, 
1991), based on biokinetic and dosimetric models of ICRP Publication 30.  The cases listed 
are those for which the effective dose coefficients are changed by more than 40% when 
weighting factors of ICRP Publication 26 are replaced by those of ICRP Publication 60.  
 
 
Radionuclides 
 
e(60):e(26) 
 
Modification(s) of weighting 
factors having greatest influence 
on effective dose coefficient 
 
Be-10, Si-32, S-35, Sc-47, V-49, Ni-66, Sr-82, Sr-89, Y-90, 
Y-91, Nb-93m, Nb-95m, Mo-99, Ru-106, Pd-103, Pd-107, 
Ag-111, Sn-117m, Sn-119m, Sn-121m, Sn-123, Sn-125, 
Sb-127, Ba-140, Ce-141, Cd-144, Pr-143, Nd-147, Pm-147, 
Pm-148, Pm-149, Tb-161, Tb-166, Er-169, Er-172, Tm-167, 
Tm-170, Tm-171, Tm-172, Yb-175, Lu-174m, Lu-177, Ta-183, 
W-185, W-188, Os-191, Os-194, Pt-193m, Pt-193, Pt-195m, 
Au-199, Th-234, Pa-233, U-237, Pu-246 
 
~1.4-1.6 
 
Introduction of weighting factor for 
colon (0.12). A substantial portion 
of total-body decays of these 
radionuclides occurs in the 
contents of the intestines. 
 
Cl-38, Cl-39, K-44, K-45, Mn-52m, Co-60m, Co-62m, Ga-65, 
Ga-70, Ge-67, Ge-75, As-69, Se-81, Br-74m, Br-74, Br-75, 
Br-80m, Br-80, Br-83, Br-84, Rb-79, Rb-81m, Rb-88, Rb-89, 
Y-94, Y-95, Mo-101, Tc-101, Tc-104, Rh-107, Ag-102, 
Ag-106, Ag-115, In-112, In-119m, Sb-120a, Sb-126m, 
Sb-128a, I-120m, I-120, I-128, I-134, Cs-125, Cs-130, 
Cs-134m, Cs-138, Ba-131m, La-143, Pr-136, Pr-144, Pr-147, 
Nd-151, Pm-141, Sm-141, Sm-155, Ho-162, Ho-164, Tm-175, 
Lu-178, Ta-182m, Ta-186, Re-177, Re-178, Re-188m, Ir-182, 
Au-201, Hg-199m, Tl-194m, Bi-214, Th-226, U-239, Am-244m 
 
~1.4-1.9 
 
Introduction of a weighting factor 
for stomach (0.12).  For the case 
of ingestion, a substantial portion 
of the total-body decays of these 
short-lived radionuclides occurs in 
the stomach contents.  
 
Tc-97m, Tc-97, Tc-98, Tc-99, Re-184m, Re-186m, Re-186, 
Re-187,Re-188, Re-189 
 
~1.4-1.7 
 
Introduction of weighting factor for 
stomach wall, a source organ in 
biokinetic models for Tc and Re. 
 
Cd-113m, Cd-113 
 
~0.5 
 
HE is dominated by a Remainder 
tissue (kidney) that contributes 
little to E due to its small mass. 
 
Te-131m, Te-132, Te-133, I-121, I-123, I-124, I-125, I-126, 
I-129, I-130, I-131, I-132m, I-132, I-133, I-135 
 
~1.4-1.7 
 
Increase in weighting factor for 
thyroid, which dominates effective 
dose for these cases. 
 
Te-123, Pb-210, Ac-227, Th-229, Th-230, Th-232, Pa-231, 
Np-236a, Np-237, Pu-238, Pu-239, Pu-240, Pu-241, Pu-242, 
Pu-244, Am-241, Am-242m, Am-243, Cm-243m Cm-245, 
Cm-246, Cm-247, Cm-248, Cm-250, Bk-247, Bk-249, Cf-249, 
Cf-250, Cf-251, Cf-252 
 
~0.4-0.6 
 
Threefold reduction of weighting 
factor for bone surface.  For many 
bone seekers, decrease in 
effective dose due to reduced 
weighting factor for bone is 
partially offset by other changes, 
e.g., introduction of weighting 
factors for liver and colon. 
 
U-230, U-232, U-233, U-234, U-235, U-236, U-238 
 
~0.4-0.5 
 
Threefold reduction of factor for 
bone surface and reduction of 
contribution of kidney dose to 
Remainder (introduction of lower 
weighting factor for Remainder 
and mass weighting for doses). 
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2.2.2. Sensitivity analysis based on updated biokinetic models for adults 
A second analysis of the sensitivity of effective dose coefficients to the change in tissue 
weighting factors was based on the updated models of the ICRP as applied to adults in Federal 
Guidance Report No. 13 (EPA, 1999).  The effective dose coefficient was again found to be only 
moderately sensitive to the change in weighting factors in most cases.  For ingestion, the ratios 
e(60):e(26) are in the range 0.44-1.9 for all radionuclides.  For inhalation of radionuclides as 
Type F, Type M, or Type S material, the ratio e(60):e(26) is in the range 0.45-3.3, 0.46-2.7, or 
0.65-2.6, respectively, and e(60) is within a factor of 2 of e(26) for approximately 78%, 94%, 
and 96%, respectively, of the radionuclides addressed in Federal Guidance Report No. 13. 
Results of the second analysis are summarized graphically in Figure 2.1 (ingestion) and 
Figures 2.2-2.4 (inhalation of Type F, M, and S material, respectively) to point out a trend in the 
ratio e(60):e(26).  That is, the ratio tends to decrease as e(60) increases.  This is because lower 
values of e(60) generally arise from short-lived radionuclides that decay largely along the route 
of intake, in or near tissues that were given explicit weighting factors in ICRP Publication 60 but 
not in ICRP Publication 26.  For the case of ingestion, an increase in the effective dose 
coefficient for short-lived radionuclides often arises from the dose to the stomach wall, which 
has a weight of 0.12 in ICRP Publication 60 but a maximum implicit weight of 0.06 as part of 
Remainder in ICRP Publication 26.  For the case of inhalation, an increase in the effective dose 
estimate for many short-lived radionuclides results from the relatively detailed representation of 
the extrathoracic (ET) airways in the updated respiratory model (ICRP, 1994b).  
 According to the updated model, the ET airways often are the most highly irradiated 
tissues of the body following inhalation of relatively short-lived radionuclides (Nelson et al., 
1997).  In the formulation of the effective dose, the ET airways are assigned to Remainder.  Due 
to a multiplicative effect in the definition of Remainder in the updated tissue weighting factors 
and the predicted doses to the ET airways, particularly the anterior nasal (ET1) region, the dose 
to the ET airways sometimes represents >50% of the calculated effective dose for inhaled 
radionuclides.  For example, this occurs for 212Pb (T1/2 = 10.6 h) and 211At (T1/2 = 7.2 h). 
The cluster of points above the horizontal equality line and the region of e(60) greater 
than 10-8 Sv Bq-1 in Fig. 2.2, 2.3, or 2.4 represents the short-lived radionuclides 214Pb, 213Bi, 
214Bi, 222Fr, 226Th, 227Pa, and 244Cf.  These radionuclides or their short-lived progeny emit alpha 
particles, with the result that the anterior nasal region of the respiratory tract is the most highly 
irradiated tissue of the body.  The “splitting” of the weighting factor for the remainder tissue 
group in the computation of e(60) results in the anterior nasal region being a major contributor to 
e(60). 
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Figure 2.1. Ratio of effective dose coefficients for ingestion 
based on the tissue weighting factors of ICRP Publication 60, 
e(60), and ICRP Publication 26, e(26). 
 
 
 
 
Figure 2.2. Ratio of effective dose coefficients for inhalation 
(Type F) based on the tissue weighting factors of ICRP 
Publication 60, e(60), and ICRP Publication 26, e(26). 
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Figure 2.3. Ratio of effective dose coefficients for inhalation 
(Type M) based on the tissue weighting factors of ICRP 
Publication 60, e(60), and ICRP Publication 26, e(26). 
 
 
 
 
Figure 2.4. Ratio of effective dose coefficients for inhalation 
(Type S) based on the tissue weighting factors of ICRP 
Publication 60, e(60), and ICRP Publication 26, e(26). 
 10
 
 
Another group of radionuclides that does not follow the general trend of declining ratios 
e(60):e(26) with decreasing values of e(60) are isotopes of iodine.  The coefficients for 
radioiodine depend largely on the estimated dose to the thyroid gland and the tissue-weighting 
factor for this tissue, which was increased from 0.03 in ICRP Publication 26 to 0.05 in ICRP 
Publication 60. Thus, the ratio e(60):e(26) could approach 0.05:0.03, or about 1.7.  This ratio is 
approximated for ingestion of most isotopes of iodine; the isolated string of points in the upper 
right portion of Figure 2.1 represents these radionuclides.  For inhalation intakes, the 
contribution of the segments of the respiratory tract to the effective dose reduces the sensitivity 
of the effective dose coefficient to the weighting factor for the thyroid gland. 
 
2.3.  Sensitivity of effective dose coefficients for children  
to changes in tissue weighting factors 
In a series of reports published between 1989 and 1996 (ICRP, 1989, 1993, 1995a, 
1995b, 1996), the ICRP provided its first recommendations of biokinetic and dosimetric models 
and dose coefficients for intake of radionuclides by members of the public.  These documents 
give dose coefficients for acute inhalation or ingestion of radionuclides for each of the following 
ages at intake:  3 mo, 1 y, 5 y, 10 y, 15 y, and adult.  The integration period is 50 y for the adult 
and to age 70 y for intake by children.  The radionuclides addressed are selected isotopes of 
hydrogen, carbon, sulfur, calcium, iron, cobalt, nickel, zinc, selenium, strontium, zirconium, 
niobium, molybdenum, technetium, ruthenium, silver, antimony, tellurium, iodine, cesium, 
barium, cerium, lead, polonium, radium, thorium, uranium, neptunium, plutonium, americium, 
and curium. 
The tissue weighting factors given in ICRP Publication 26 (1977) and Publication 60 
(1991) are independent of age.  Effective dose coefficients given in Part 1 of the series on intake 
of radionuclides by members of the public (ICRP, 1989) are based on tissue weighting factors 
given in ICRP Publication 26.  Coefficients given in later parts of the series are based on 
weighting factors recommended in ICRP Publication 60, which appeared shortly after 
publication of Part 1 of the series.  The dose coefficients tabulated in Part 1 were updated in Part 
2 (ICRP, 1993) for ingestion and Part 4 (ICRP, 1995a) for inhalation, to reflect the updated 
recommendations of ICRP Publication 60 as well as updates of some models used in Part 1. 
 For children, conclusions regarding the sensitivity of effective dose coefficients to 
changes in the tissue weighting factors are not much different than indicated earlier for adults.  
Effective dose coefficients for children usually are changed by less than a factor of 2, and in 
many cases are virtually unchanged, by switching between the tissue weighting factors of ICRP 
Publication 26 and Publication 60.  This is indicated, for example, by comparing age-specific 
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effective dose coefficients given in Part 1 of the series on occupational intakes (ICRP 
Publication 56, 1989, which applied the weighting factors of ICRP Publication 26) and the 
modifications of those coefficients in later documents (ICRP, 1993; ICRP, 1995a) to reflect the 
recommendations of ICRP Publication 60.  As is the case for the adult, the largest effects of the 
updated tissue weighting factors on dose coefficients for children are seen in cases where the 
effective dose is dominated by the dose to bone surface, thyroid, colon, or stomach.  Recall that 
substantial modifications were made in weighting factors for bone surface and thyroid, and that 
colon and stomach are addressed explicitly in the updated tissue weighting factors but not in 
those given in ICRP Publication 26.  Occasionally, the decrease in the weighting factor for 
Remainder leads to a substantial change in the effective dose coefficient, and the peculiarities 
associated with the ET region of the updated lung model also come into play in the same cases as 
for adults.  In general, the numerical effects of the changes in tissue weighting factors indicated 
in Tables 2.2 and 2.3 apply with only minor changes for children. 
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 3.  REVISION OF THE RESPIRATORY TRACT MODEL 
 
 3.1.  Background 
An important change in the ICRP’s methodology since the appearance of ICRP 
Publication 30 is the introduction of a relatively detailed, physiologically realistic model of the 
respiratory tract (ICRP, 1994b).  In contrast to the ICRP’s previous respiratory model, the 
updated model addresses differences with age, gender, breathing rate, and other factors affecting 
deposition of inhaled material in the respiratory tract.  For example, age-specific deposition 
fractions for different regions of the tract are provided for consideration of environmental 
intakes, and different patterns of deposition within the lung are also provided for occupational 
and environmental intakes by the adult to account for differences in breathing rates and mouth 
versus nose breathing.  Also, in contrast to the earlier model, the dosimetric features of the 
updated model represent an attempt to address the heterogeneous distribution of radiosensitive 
cells within the respiratory tract. 
  Along with the introduction of a new respiratory model, the ICRP changed its 
recommendation for a default particle size for assessment of occupational intake, from 1 µm to 5 
µm (activity median aerodynamic diameter, or AMAD).  Depending to some extent on the half-
life of the radionuclide and the types and energies of emitted radiations, the change in the default 
particle size sometimes leads to noticeable changes in dose estimates for occupational intakes 
due to differences in total or regional deposition of 1- and 5-µm particles in the respiratory tract. 
The ICRP’s previous and updated respiratory tract models are compared in the following 
sections.  For brevity, the respiratory model used in ICRP Publication 30 is referred to as the 
TGLM (Task Group Lung Model), and the model used in ICRP Publication 68 is referred to as 
the updated model.  The TGLM was introduced in a publication by the ICRP Task Group on 
Lung Dynamics (1966) and was later summarized and applied in ICRP Publication 19 (1972) 
and ICRP Publication 30 (1979, 1980, 1981, 1988a).  The updated model, also known as the 
Human Respiratory Tract Model or HRTM, was introduced in ICRP Publication 66 (1994b), 
where its basis and features are described. 
 
 3.2. Description of the TGLM 
The structure of the TGLM is shown in Figure 3.1.  The model includes four main 
regions: nasal-pharynx (NP), tracheobronchial (TB), pulmonary (P), and lymphatic (L).  Inhaled 
material is deposited in regions NP, TB, and P, with regional deposition depending on the size 
(AMAD) of the inspired particles.  A given chemical or physical form of a radionuclide is  
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Figure 3.1.  Structure of the Task Group Lung Model (TGLM) 
formerly used by the International Commission on Radiological 
Protection (ICRP, 1966, 1979). 
 
 
 
assigned to one of three clearance classes, D (days), W (weeks), or Y (years), corresponding, 
respectively, to rapid, intermediate, or slow clearance of material deposited in the respiratory 
passages.  Removal half-times are assumed to be independent of particle size. 
Parameter values for the TGLM are given in Table 3.1 for a particle size of 1 µm 
(AMAD).  For this particle size, fractional deposition of inhaled material in the total respiratory 
tract is assumed to be 0.63, of which 0.25 is assigned to NP, 0.08 to TB, and 0.25 to P.  For a 
long-lived radionuclide, fractional transfer of inhaled activity to blood is estimated as 0.48 + 
0.15⋅f1 for Class D, 0.12 + 0.51⋅f1 for Class W, and 0.05 + 0.58⋅f1 for Class Y material, where f1 
represents fractional absorption of swallowed activity (paths b, d, k, and l).  
The dose to the lungs is based on the assumption that the total activity in the TB, P, and 
LN regions is uniformly distributed in the total blood-filled lungs. 
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Table 3.1.   Parameters of the TGLM for 1-µm particles (AMAD).  The biological half-
times, T1/2, are assumed to be independent of particle size. 
 
 
 
Class 
 
D 
 
W 
 
Y 
 
 
Region and 
fractional 
deposition 
 
 
 
 
Path 
 
T1/2 (d) 
 
Fraction 
 
T1/2 (d) 
 
Fraction 
 
T1/2 (d) 
 
Fraction 
 
a 
 
0.01 
 
0.5 
 
0.01 
 
0.1 
 
0.01 
 
0.01 
 
NP 
(0.3)  
b 
 
0.01 
 
0.5 
 
0.4 
 
0.9 
 
0.4 
 
0.99 
 
c 
 
0.01 
 
0.95 
 
0.01 
 
0.5 
 
0.01 
 
0.01 
 
TB 
(0.08)  
d 
 
0.2 
 
0.05 
 
0.2 
 
0.5 
 
0.2 
 
0.99 
 
e 
 
0.5 
 
0.8 
 
50 
 
0.15 
 
500 
 
0.05 
 
f 
 
NA 
 
NA 
 
1.0 
 
0.4 
 
1.0 
 
0.4 
 
g 
 
NA 
 
NA 
 
50 
 
0.4 
 
500 
 
0.4 
 
P 
(0.25) 
 
h 
 
0.5 
 
0.2 
 
50 
 
0.05 
 
500 
 
0.15 
 
L 
 
i 
 
0.5 
 
1.0 
 
50 
 
1.0 
 
1000 
 
0.9 
 
 3.3. Description of the updated respiratory model 
 
The structure of the updated respiratory tract model is shown in Figure 3.2.  The model 
divides the respiratory system into extrathoracic (ET) and thoracic regions.  The airways of the 
ET region are further divided into two categories:  the anterior nasal passages, in which deposits 
are removed by extrinsic means such as nose blowing, and the posterior nasal passages including 
the nasopharynx, oropharynx, and the larynx, from which deposits are swallowed.  The airways 
of the thorax include the bronchi (compartments labeled BBi), bronchioles (compartments 
labeled bbi), and alveolar region (compartments labeled AIi).  Material deposited in the thoracic 
airways may be cleared into blood by absorption, to the GI tract by mechanical processes (that is, 
transported upward and swallowed), and to the regional lymph nodes via lymphatic channels. 
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Figure 3.2.  Structure of the ICRP’s current respiratory model (ICRP, 1994b). 
 
 
 
The number of compartments in each region was chosen to allow duplication of the 
different kinetic phases observed in humans or laboratory animals.  Particle transport rates 
shown beside the arrows in Figure 3.2 are reference values in units of d-1.  For example, particle 
transport from bb1 to BB1 is assumed to occur at a fractional rate of 2 d-1, and particle transport 
from ET2 to the gastrointestinal tract is assumed to occur at a fractional rate of 100 d-1. 
For an inhaled compound, the mechanical clearances of particles indicated in Figure 3.2 
are in addition to dissolution rates and absorption to blood, which depend on the element and the 
chemical and physical form in which it is inhaled.  Although the model permits consideration of 
compound-specific dissolution rates, a particulate is generally assigned to one of three default 
absorption types:  Type F, representing fast dissolution and a high level of absorption to blood; 
Type M, representing an intermediate rate of dissolution and an intermediate level of absorption 
to blood; and Type S, representing slow dissolution and a low level of absorption to blood.  
Ideally, the user has information on the physical and chemical properties of the material of 
interest. In practice, properties of inhaled material often are not known. 
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The fractional rates of absorption (d-1) assigned to the default types are 
Type F: 100 , 
Type M: 10 e - 100 t + 0.005 e- 0.005 t , 
Type S: 0.1 e - 100 t + 0.0001 e - 0.0001 t , 
where t is time (days) since deposition. 
In contrast to the TGLM, dosimetry for the updated model addresses the heterogeneous 
distribution of radiosensitive cells in the respiratory tract.  Six target tissues are considered:  
keratinized epithelium of the skin in the anterior part of the nose (ET1); stratified squamous 
epithelium of the main extrathoracic airways (ET2); ciliated epithelium of the bronchi (BB); 
ciliated epithelium of the bronchioles (bb); alveolar-interstitium (AI); and thoracic and 
extrathoracic lymph nodes (LNTH and LNET, respectively).  Reference masses of the target 
regions of the respiratory tract of the adult male are given in Table 3.2. 
The lung dose is defined as a weighted average of the doses to different regions of the 
lungs.  The following weights are assigned:  bronchial region, 0.333, divided evenly between the 
basal and secretory cells; secretory cells of the bronchiolar region, 0.333; the alveolar-interstitial 
region, 0.333; and the thoracic lymph nodes, 0.001.  The dose to the extrathoracic regions, 
including its lymph nodes, is considered as part of Remainder tissue.  Although equal weights 
are given to the bronchial, bronchiolar, and alveolar-interstitial regions, the ICRP (1994b) points 
out the possibility, in view of the regional distribution of spontaneous lung cancers in the general 
non-smoking population, that uniform irradiation of the lungs could result in a greater risk to the 
bronchial region than to the other regions of the lung. 
 
 
Table 3.2.  Reference masses of target regions in the respiratory tract of the adult male. 
 
 
Tissue 
Reference mass for the adult 
male 
(g) 
Extrathoracic 1 - Basal Cells 0.0200 
Extrathoracic 2 - Basal Cells 0.450 
Bronchial - Basal Cells 0.432 
Bronchial - Secretory Cells 0.864 
Bronchiolar - Secretory Cells 1.94 
Alveolar-Interstitial 1100 
Lymph Nodes - Extrathoracic 15.0 
Lymph Nodes - Thoracic 15.0 
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3.4.  Differences in predictions of the two respiratory models for workers 
 
3.4.1. Total and regional deposition of inhaled particles 
There is not an exact correspondence between the different regions of the updated 
respiratory model and the TGLM, but the ET region of the updated model is broadly comparable 
to the NP region of the TGLM; the bronchi (BB) and bronchioles (bb) combined are comparable 
to the TB region; and the AI region is comparable to the P region.  The baseline Types F, M, and 
S associated with the updated model are broadly similar to the clearance Classes D, W, and Y, 
respectively, associated with the TGLM.  In ICRP Publication 68 (1994a), compounds of an 
element for which clearance was given as Classes D, W, and Y in ICRP Publication 30 were 
assigned to absorption types F, M, and S, respectively.  
Compared with the TGLM, the updated model generally predicts lower total deposition 
in both the total respiratory tract and lower lungs (pulmonary or alveolar-interstitial regions).  
This is illustrated in Figure 3.3 for particle sizes 0.2, 1.0, and 5.0 µm (AMAD).  Predictions of 
the updated model are based on reference breathing rates for occupational exposure. 
 
Figure 3.3. For three different particle sizes, deposition fractions for deep 
lungs and total respiratory tract predicted by the TGLM (ICRP, 1966) 
and the ICRP’s updated respiratory model (ICRP, 1994b).  Predictions of 
the updated model are based on reference breathing rates for 
occupational exposure. 
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Regional deposition fractions predicted by the two models are compared in Table 3.3 for 
particle sizes 1.0 and 5.0 µm, the default sizes used in ICRP Publication 30 and Publication 68, 
respectively.  The dose coefficients for workers given in Publication 30 and Publication 68 are 
based on somewhat different regional distributions.  For example, Publication 30 assigns 30% of 
deposited material to nose and pharynx and 25% to deep lung (pulmonary).  Publication 68 
assigns 74% to the extrathoracic region and ~5% to the deep lung (alveolar-interstitial region). 
 
3.4.2.  Rate of clearance of deposited activity from the respiratory tract  
Predicted retention times for long-lived radionuclides within the main divisions of the 
updated model are compared in Figure 3.4 with predictions of the TGLM.  In this figure, “B” 
represents the combined activity in the bronchi and bronchioles, as predicted by the updated 
model. Comparisons are made for acute inhalation of 1-µm particles by a worker.  Predictions of 
the updated model for Types F, M, and S are compared with predictions of the TGLM for 
Classes D, W, and Y, respectively. 
    For highly soluble material (Class D or Type F), the updated model predicts much faster 
removal from the thoracic region (B + AI or TB +P) than does the TGLM.  However, the 
updated model predicts slower removal from the extrathoracic region (ET or NP), due to 
relatively slow removal from the anterior part of the nose (compartment ET1 in the updated 
model). 
  
 
Table 3.3. Regional deposition fractions predicted by the TGLM and updated respiratory 
models for 1-µm and 5-µm particles (AMAD), the default particle sizes for occupational 
intake used in ICRP Publication 30 and Publication 68, respectively. 
 
 
Deposition fraction 
 
 
 
Respiratory tract 
model and ICRP 
publication 
 
 
 
 
 
Region 
 
 
 
1 µm 
 
 
 
5 µm 
 
Default particle size 
(1 µm in Pub. 30;  
5 µm in Pub. 68) 
 
Updated (Pub. 68) 
TGLM (Pub. 30) 
 
ET  
NP 
 
0.38 
0.30 
 
0.74 
0.74 
 
0.74 
0.30 
 
Updated (Pub. 68) 
TGLM (Pub. 30) 
 
BB+bb 
TB 
 
0.029 
0.08 
 
0.029 
0.08 
 
0.029 
0.08 
 
Updated (Pub. 68) 
TGLM (Pub. 30) 
 
AI 
P 
 
0.11 
0.25 
 
0.053 
0.088 
 
0.053 
0.25 
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Figure 3.4.  Retention curves for compartments of the TGLM (ICRP, 
1966) and updated ICRP respiratory model (ICRP, 1994b).
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For moderately soluble (Class W or Type M) or relatively insoluble (Class Y or Type S) 
material, the updated model depicts more tenacious retention in the thoracic region than does the 
TGLM.  For times remote from inhalation, the content of the lungs as predicted by the updated 
model is several times greater than that predicted by the TGLM.  This difference between the 
two models can have important implications with regard to interpretation of bioassay data.  As 
illustrated later, backward calculation of an inhalation intake based on a low level of activity in 
the lungs or urine at times remote from exposure can yield much greater estimates of intake if 
based on the TGLM than if based on the updated model. 
 
3.4.3.  Rate of absorption from the respiratory tract to blood 
Compared with the TGLM, the updated model generally predicts lower absorption from 
the respiratory tract to blood for a given particle size, at least for particle sizes commonly 
encountered in the work place or environment.  This is illustrated in Table 3.4 for 1-µm particles, 
for which predicted total absorption is about two times greater for Class D than Type F, about 
one-third greater for Class W than Type M, and about four times greater for Class Y than Type 
S. The values given in Table 3.4 are in addition to gastrointestinal absorption of activity that is 
swallowed after removal from the respiratory tract by mucociliary transport. 
 
Table 3.4.  Comparison of predictions of the TGLM and updated respiratory tract models: 
 cumulative absorption to blood as a function of time following inhalation of 1-µm particles 
(AMAD).  Predictions are for occupational exposure. 
 
 
Cumulative absorption (fraction of inhaled amount) 
 
 
Time 
(d) 
 
Class D 
 
Type F 
 
Class W 
 
Type M 
 
Class Y 
 
Type S 
0.01 0.12 0.18 0.036 0.018 0.0000 0.00018 
0.1 0.26 0.24  0.071 0.024 0.0039 0.00024 
1 0.40 0.24  0.072 0.025 0.0039 0.00025 
10 0.48 0.24  0.076 0.029 0.0041 0.00036 
100 0.48 0.24  0.10 0.057 0.0057 0.0011 
1,000 0.48 0.24  0.12 0.089 0.022 0.0074 
10,000 0.48 0.24  0.12 0.089 0.05 0.011 
20,000 0.48 0.24  0.12 0.089 0.05 0.012 
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The above comparisons are based on a particle size of 1 µm (AMAD), the default value 
applied in ICRP Publication 30.  Current ICRP documents (ICRP, 1994a, 1994b) recommend a 
default particle size of 5 µm for occupational intakes.  As indicated in Table 3.5, the predicted 
pattern of absorption to blood differs for 1-µm and 5-µm particles.  According to the updated 
model, the rate of absorption to blood initially is higher for 5-µm particles than for 1-µm 
particles because the larger particles deposit mainly in the upper portions of the tract, where the 
rate of absorption to blood is relatively high.  After material has largely cleared from the upper 
respiratory tract, predicted absorption is lower for 5-µm particles than for 1-µm particles because 
of the relatively low deposition of the larger particles in the lower regions of the tract. 
For highly soluble particles (Type F), total absorption to blood is predicted by the 
updated model to be greater for 5-µm particles than for 1-µm due to elevated deposition of the 
larger particles in the upper respiratory tract and the subsequently rapid absorption of activity 
from that region to blood (Table 3.5).  For particles that dissolve more slowly (Type M and Type 
S), the updated model predicts that a substantial portion of the deposited particles is cleared to 
the gastrointestinal tract by mechanical transport before there is sufficient dissolution to allow 
absorption of the radionuclide into blood.  The net effect for Type M or S is that predicted 
absorption from the respiratory tract is lower for 5-µm than for 1-µm particles (Table 3.5). 
 
Table 3.5.  Comparison of two sets of predictions of the updated respiratory model:  
cumulative absorption from respiratory tract to blood as a function of time following 
inhalation of 1-µm and 5-µm particles (AMAD).  Predictions are for occupational exposure. 
 
 
Cumulative absorption (fraction of inhaled amount) 
 
Type F 
 
Type M 
 
Type S 
 
 
 
Time 
(d)  
1 µm 
 
 5 µm 
 
1 µm 
 
 5 µm 
 
1 µm 
 
 5 µm 
0.01 0.18 0.22 0.018 0.022 0.00018 0.00022 
0.1 0.24 0.28 0.024 0.028 0.00024 0.00028 
1 0.24 0.28 0.025 0.028 0.00025 0.00029 
10 0.24 0.28 0.029 0.031 0.00036   0.00034 
100 0.24 0.28 0.057 0.045 0.0011 0.00074 
1,000 0.24 0.28 0.089 0.061 0.0074 0.0029 
10,000 0.24 0.28 0.089 0.061 0.011 0.0059 
20,000 0.24 0.28 0.089 0.061 0.012 0.0064 
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3.4.4.  Implications of updated respiratory model for lung dose 
The predictive differences between the TGLM and updated respiratory models and the 
different dosimetric assumptions used with the two models often result in substantially different 
estimates of lung dose from inhaled radionuclides.  The magnitude and direction of the 
differences vary with the solubility of the inhaled material, the half-time of the radionuclide and 
its radio active progeny, and the types and energies of emitted radiations. 
For selected radionuclides, comparisons were made of the 50-y equivalent dose to the 
lungs as predicted by the models of ICRP Publication 30 (that is, the TGLM together with the 
systemic models and f1 values used in ICRP Publication 30) and the models of ICRP Publication 
68 (that is, the updated respiratory model together with the systemic biokinetic models and f1 
values used in ICRP Publication 68).  Two sets of comparisons were made, one assuming 
inhalation of 1-µm particles, and the other assuming inhalation of the default particles sizes, that 
is, 1 µm in the calculations based on models of ICRP Publication 30 and 5 µm in the calculations 
based on models of Publication 68.  Predictions of the updated models for Type F, M, or S were 
compared with predictions of the previous models for Class D, W, or Y, respectively. 
Results are shown in Table 3.6.  The updated model generally gives much smaller 
estimates of lung dose for relatively long-lived radionuclides inhaled in insoluble form because it 
predicts relatively low deposition of material in the deep lungs compared with the TGLM, and it 
is activity in the deep lungs that generally accounts for much of the lung dose after inhalation of 
long-lived radionuclides in insoluble form.  For short-lived radionuclides in moderately soluble 
or insoluble form, the updated model often yields higher doses than the TGLM because of the 
relatively high dose estimates for a small mass of sensitive tissue in the bronchi and bronchioles. 
 
3.4.5.  Changes in the treatment of gases and vapors 
In contrast to inhaled particulates, the deposition and retention of gases and vapors in the 
respiratory tract is material specific, depending on the chemistry of the compound.  The TGLM 
does not address gases and vapors, and no attempt was made in ICRP Publication 30 to provide a 
uniform treatment of gases or vapors. 
The updated respiratory model divides gases and vapors into three general classes, 
identified as SR-1, SR-2, and SR-0.  Class SR-1 represents moderately soluble or reactive gases, 
for which consideration is given to retention in respiratory tract tissues and to uptake to the 
systemic circulation.  Class SR-2 represents highly soluble or reactive gases or vapors, for which 
complete and instantaneous systemic uptake of the inhaled activity is assumed.  Class SR-0  
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Table 3.6.  For selected radionuclides, comparison of lung doses predicted by the models of 
ICRP Publication 30 and Publication 68 for acute inhalation of particulates. 
 
Ratio of lung doses (50-y) 
ICRP Pub. 68 : ICRP Pub. 30 
 
 
 
Radio-
nuclide 
 
 
 
 
Half-life 
 
 
 
 
Class/Type 
 
Based on  
1 µm 
(AMAD) 
 
Based on default 
particle sizes (1 µm for 
Pub. 30 and 5 µm for 
Pub. 68) 
Co-60 5.271 y M/W 1.4 0.9 
  S/Y 0.49 0.28 
Sr-90 29.12 y F/D 0.17 0.21 
  S/Y 0.42 0.22 
Y-90 64.0 h M/W 0.73 0.51 
  S/Y 0.79 0.55 
Ru-106 368.2 d M/W 0.89 0.49 
  S/Y 0.48 0.25 
Pb-212 10.64 h F/D 0.04 0.05 
  M/W 3.9 3.5 
Th-232 1.4E10 y M/W 1.7 1.1 
  S/Y 0.16 0.08 
U-234 2.45E5 y F/D 1.1 1.3 
  M/W 1.5 1.0 
Pu-239 2.41E4 y M/W 1.7 1.2 
  S/Y 0.25 0.15 
 
 
 
represents relatively insoluble or non-reactive gases or vapors, for which consideration is given 
to internal irradiation from gas within the respiratory tract.  Within this general framework, gases 
and vapors are assigned material-specific parameter values when information is available or 
default values when such information is lacking.  
With regard to treatment of gases and vapors, an important feature of the updated 
respiratory model is the postulation of “bound” compartments within the BB, bb, and AI regions. 
According to the model, material reaching these compartments is not cleared by particle 
transport processes but is available for gradual absorption to blood.  For some gases or vapors in 
Class SR-1, assignment of a portion of the inhaled activity to the bound compartments leads to 
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dose estimates that differ noticeably from those given in ICRP Publication 30.  Especially large 
differences in the updated and previous dose coefficients are seen for mercury vapor (Table 3.7). 
For all major mercury isotopes except 194Hg (T1/2 = 260 y), effective doses given in ICRP 
Publication 68 are substantially greater than values given in ICRP Publication 30.  The reasons 
for such large differences in effective dose coefficients for mercury vapor were investigated.  
According to the model for mercury vapor given in ICRP Publication 30, 70% of inhaled 
mercury vapor is deposited in the lungs, and all of the deposited mercury is absorbed to blood 
with a half-time of 1.7 d.  In effect, mercury vapor is assumed to be distributed uniformly in the 
lungs.  The model of ICRP Publication 68 assumes the same kinetics for mercury vapor, but 
assigns a different distribution:  10% is assigned to the bound compartment of the large bronchi 
(BB), 20% to the bound compartment of the small bronchi (bb), and 40% to the bound 
compartment of the bound compartment of the alveolar interstitial (AI) region. 
 The ICRP’s assumptions are not consistent with current information on the gross 
distribution or residence time of mercury vapor in the respiratory tract (Leggett et al., 2001).  It 
appears that inhaled mercury vapor deposits largely in the AI region, that most of the deposited 
mercury is nearly instantaneously absorbed to blood, and that the remainder may have multiple 
components of retention in the lungs. 
 
 
Table 3.7.  Comparison of dose coefficients for inhalation of radioactive 
mercury vapor by a worker, based on models of ICRP Publication 30 and 
Publication 68.  The systemic biokinetic model for mercury is essentially 
the same in the two documents. 
 
 
Ratio of dose coefficients, 
ICRP 68 : ICRP 30 
 
 
 
Radionuclide 
 
 
 
Half-life  
Effective 
Hg-193 3.5 h 23 
Hg-193m 11.1 h 15 
Hg-194 260 y 0.85 
Hg-195 9.9 h 25 
Hg-195m 41.6 h 20 
Hg-197 64.1 h 23 
Hg-197m 23.8 h 18 
Hg-199m 42.6 h 9.7 
Hg-203 46.6 d 4.0 
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An alternate model of the distribution and retention of inhaled mercury vapor in the 
respiratory tract has been proposed (Leggett et al., 2001).  The proposed model differs from that 
of ICRP Publication 68 in several ways.  As a minor change, total deposition in the respiratory 
tract is increased from 70% to 80%.  More importantly, a different regional distribution in the 
respiratory tract is assumed: 2% in the extrathoracic region (sub-region ET2 in the updated 
model), 1% in the large bronchi (BB), 2% in the small bronchi (bb); and 75% in the alveolar-
interstitial region (AI).  In addition, multiple retention components are assumed.  A portion of 
the mercury deposited in AI equivalent to 70% of the deposition in the respiratory tract (i.e., 
56% of inhaled mercury) is assumed to be absorbed to blood at a rate of 1000 d-1.  Of the 
remaining activity in all regions of the respiratory tract, 80% is assumed to be absorbed to blood 
with a half-time of 8 h and 20% is assumed to be absorbed with a half-time of 5 d. 
The effect of the proposed model revisions on estimates of effective dose and integrated 
dose to lungs and kidneys due to inhalation of isotopes of mercury as vapor are summarized in 
Table 3.8.  In this comparison, both the ICRP’s respiratory model and the proposed revision of 
the model were coupled with the ICRP’s current systemic biokinetic model for mercury.  The 
revisions generally lead to a substantial decrease in the estimated lung dose due to a much 
smaller integrated activity in the lungs and an increase in the dose to kidneys and other systemic 
tissues due to the higher assumed deposition and more rapid movement of activity to the 
systemic circulation.  The extent of changes in estimated doses depends on the radiological half-
life of the radioisotope and the types and energies of its emitted radiations.   
 
3.5.  Comparison of the updated respiratory model and TGLM 
with regard to evaluation of environmental exposures 
Although the TGLM was designed and intended for application to occupational intakes, 
it has also been applied to environmental exposures.  In contrast to the TGLM, the updated 
respiratory model was designed to address environmental as well as occupational intakes.  For 
example, the updated model includes ventilation rates and deposition fractions that depend on 
age, gender, and level of physical activity (Figures 3.5 and 3.6, Table 3.9). 
On the other hand, parameters of the updated model describing mechanical clearance of 
material from the lungs or absorption of activity to blood are assumed to be independent of age 
and gender.  Because of the smaller mass of the lung tissue in infants and children (Table 3.10) 
and the fact that deposition per unit activity inhaled does not differ markedly with age (Figure 
3.6, Table 3.9), the estimated lung dose per unit inhaled is often much greater in children than in 
adults.  When adjusted to account for the smaller quantities of air inhaled at younger ages, 
however, the lung doses do not vary substantially with age (Table 3.11). 
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Table 3.8.  Comparison of dose coefficients for inhaled mercury vapor given in ICRP 
Publication 68 with values derived from a revised model (Leggett et al., 2001). 
 
 
Ratio of dose coefficients, proposed model: ICRP 
68 
 
 
 
Radionuclide 
 
 
 
Half-life  
Lung 
 
Kidneys 
 
Effective 
Hg-193 3.5 h 0.08 4.1 0.12 
Hg-193m 11.1 h 0.07 3.1 0.12 
Hg-194 260 y 0.74 1.1 1.1 
Hg-195 9.9 h 0.07 2.6 0.11 
Hg-195m 41.6 h 0.06 1.9 0.10 
Hg-197 64.1 h 0.06 1.7 0.10 
Hg-197m 23.8 h 0.06 2.2 0.10 
Hg-199m 42.6 h 0.11 15 0.18 
Hg-203 46.6 d 0.09 1.2 0.26 
 
 
 
 
Table 3.9.  Total and regional deposition fractions as a function of age, as predicted by the 
updated respiratory model for inhalation of 1-µm particles (AMAD). 
 
Age  
 
Region 
 
100 d 
 
1 y 
 
5 y 
 
10 y 
 
15 y 
Adult 
member of 
public 
 
Worker 
AI 0.0856 0.0964 0.0985 0.0951 0.107 0.115 0.107 
bbe 0.0204 0.0171 0.0185  0.017   0.020 0.0195 0.0165 
Bbi 0.0104 0.0104 0.0104 0.0117 0.0169 0.0129 0.0124 
ET 0.482 0.484 0.397 0.406 0.320 0.339 0.376 
Total 0.598 0.608 0.524 0.530 0.464 0.486 0.512 
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Figure 3.5.  Reference age- and gender-specific inhalation rates 
used with the updated respiratory model (ICRP, 1994b). 
 
 
Figure 3.6.  Deposition in deep lungs and total respiratory tract 
as a function of age, as predicted by the ICRP’s updated 
respiratory model (ICRP, 1994b). 
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Table 3.10.  Reference masses of target tissues in the updated respiratory 
tract model for ages 1 y and 10 y, relative to values for the adult male. 
 
Ratio, mass at given age : mass in adult Region  
1 y 10 y 
Subregions of ET 0.207 0.632 
Subregions of BB 0.359 0.719 
bb 0.306 0.670 
AI 0.137 0.452 
LN 0.137 0.452 
 
 
Table 3.11.  Examples of differences with age in estimates of lung dose, based on the 
updated respiratory model.  Two comparisons are made for each radionuclide: dose per 
unit intake, and dose per unit exposure, where the latter refers to dose per unit intake 
normalized to the age-specific ventilation rate. 
 
Ratio of estimated lung dose, 
Updated model (age-specific): 
TGLM (adult) 
 
Radio-
nuclide 
 
 
Half-life 
 
 
Type 
 
Referent (per 
unit intake or 
unit exposure} 1 y 10 y Adult 
Co-60 5.271 y M Intake 4.5 2.0 1.5 
   Exposure 1.1 1.4 1.5 
Sr-90 29.12 y F Intake 1.2 0.34 0.17 
   Exposure 0.28 0.23 0.17 
Pb-212 10.64 h F Intake 0.20 0.07 0.04 
   Exposure 0.05 0.05 0.04 
Th-232 1.4E10 y M Intake 5.9 2.6 1.9 
   Exposure 1.4 1.8 1.9 
Th-232 1.4E10 y S Intake 0.38 0.18 0.17 
   Exposure 0.09 0.12 0.17 
U-234 2.45E5 y F Intake 2.6 1.4 1.1 
   Exposure 0.61 1.0 1.1 
U-234 2.45E5 y M Intake 5.6 2.4 1.7 
   Exposure 1.3 1.7 1.7 
Pu-239 2.41E4 y M Intake 6.2 2.7 1.9 
   Exposure 1.5 1.9 1.9 
Pu-239 2.41E4 y S Intake 0.82 0.35 0.27 
   Exposure 0.19 0.24 0.27 
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4.  CHANGES IN f1 VALUES 
 
 4.1.  Description of the ICRP’s gastrointestinal tract model 
The ICRP’s model for transit of material through the gastrointestinal tract has not been 
changed since its appearance in ICRP Publication 30 (1979), but the ICRP has since updated 
several of its reference values for gastrointestinal uptake of elements (f1 values).  The updated f1 
values are used in ICRP Publication 68 (1994a).  In contrast to ICRP Publication 30, some of the 
systemic biokinetic models used in ICRP Publication 68 depict feedback of activity from the 
systemic tissues and fluids into the contents of the tract. 
The gastrointestinal transit model, shown in Figure 4.1, divides the tract into four 
segments or compartments:  stomach (St), small intestine (SI), upper large intestine (ULI), and 
lower large intestine (LLI), and depicts first-order transfer of material from one segment to the 
next.  Material is assumed to transfer from St to SI at the fractional rate of 24 d-1, from SI to ULI 
at 6 d-1, from ULI to LLI at 1.8 d-1, and from LLI to Feces at 1 d-1. 
Absorption of ingested material to blood generally is assumed to occur only in SI and is 
described in terms of an element-specific f1 value.  In the absence of radioactive decay, the 
fraction f1 of ingested material moves from SI to BLOOD and the fraction 1-f1 moves from SI to 
ULI and is excreted in feces.  The transfer coefficient from SI to BLOOD is 6f1 / (1-f1) d
-1. 
 
 
 
Figure 4.1.  Structure of the ICRP’s model 
of the gastrointestinal tract (ICRP, 1979). 
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 4.2. Revisions of f1 values for workers 
The ICRP’s series of documents on doses to members of the public (ICRP, 1989, 1993, 
1995a, 1995b, 1996) provides updated information on gastrointestinal uptake of 31 elements:  
hydrogen, carbon, sulfur, calcium, iron, cobalt, nickel, zinc, selenium, strontium, zirconium, 
niobium, molybdenum, technetium, ruthenium, silver, antimony, tellurium, iodine, cesium, 
barium, cerium, lead, polonium, radium, thorium, uranium, neptunium, plutonium, americium, 
and curium.  In some cases, the updated information is relevant to occupational as well as 
environmental intakes.  For example, in ICRP Publication 69 (1995a), the f1 value for uranium in 
the adult was reduced from 0.05 (ICRP Publication 30, 1979) to 0.02 on the basis of generally 
consistent results from environmental studies and controlled experimental studies on human 
subjects, and several of the studies appear to be applicable both to occupational and 
environmental intakes.  In such cases, the f1 values adopted by the ICRP for adult members of 
the public were also applied to workers in ICRP Publication 68.  In other cases, values selected 
for adult members of the public were not applied in Publication 68 because they were based 
primarily on forms of radionuclides that were unlikely to be encountered in occupational intakes. 
For example, an f1 value for polonium of 0.5 was selected for adult members of the public on the 
basis of data for organically bound polonium.  Because occupational intakes are more likely to 
involve inorganic than organic forms of polonium, the f1 value of 0.1 applied to polonium in 
ICRP Publication 30 was also used in Publication 68. 
The f1 values applied in ICRP Publication 68 are compared in Table 4.1 with values 
applied in Publication 30.  The largest absolute change from f1 values given in ICRP Publication 
30 was a decrease from 0.3 to 0.1 for some forms of cobalt.  Fairly large relative changes (say, 
by 50% or more) were made for several elements with low absorption such as actinide and 
lanthanide elements.   
 
 4.3. Effects of the modifications of f1 values on dose coefficients for workers 
   The effect of the modifications of f1 values on dose coefficients for workers is examined 
in Table 4.2.  For selected radionuclides, comparisons were made of the effective dose as well as 
dose coefficients for colon and red marrow, based on the previous and updated f1 values but 
leaving all other models and assumptions unchanged.  The systemic biokinetic models of ICRP 
Publication 68 were used in this analysis. 
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Table 4.1.  Comparison of f1 values applied in ICRP Publication 30 and Publication 68. 
 
 
Element 
 
ICRP Pub. 30 
 
ICRP Pub. 68 
 
Basis for revised f1  
 
Cobalt 
  Other compounds 
  Oxides, hydroxides  
 
 
0.3 
0.05 
 
 
0.1 
0.05 
 
 
ICRP Pub. 67 (1993) 
 
Tellurium 
 
0.2 
 
0.3 
 
ICRP Pub. 67 (1993) 
 
Cerium 
 
0.0003 
 
0.0005 
 
ICRP Pub. 67 (1993) 
 
Lanthanum, 
europium  
 
0.001 
 
0.0005 
 
Analogy with cerium; 
ICRP Pub. 67, 1993 
 
Other lanthanides 
 
0.0003 
 
0.0005 
 
Analogy with cerium; 
ICRP Pub. 67, 1993 
 
Thorium 
 Oxides, hydroxides 
 Other compounds 
 
 
0.0002 
0.0002 
 
 
0.0002 
0.0005 
 
 
ICRP Pub. 69 (1995a) 
 
Uranium 
 
0.05 (soluble) 
0.002 (insoluble) 
 
0.02 (soluble) 
0.002 (insoluble) 
 
ICRP Pub. 69 (1995a) 
 
Plutonium 
 Oxides 
 Nitrate 
 Other compounds 
 
 
0.00001 
0.0001 
0.0001 (Part 1) 
0.001 (Part 4) 
 
 
0.00001 
0.0001 
0.0005 
 
 
ICRP Pub. 67 (1993) 
 
Neptunium 
 
0.01 (Part 2) 
0.001 (Part 4) 
 
0.0005 
 
ICRP Pub. 67 (1993) 
 
Americium  
 
0.0005 (Part 1) 
0.001 (Part 4) 
 
0.0005 
 
ICRP Pub. 67 (1993) 
 
Curium 
 
0.0005 (Part 1) 
0.001 (Part 4) 
 
0.0005 
 
ICRP Pub. 71 (1995b) 
 
Actinium, 
protactinium 
 
0.001 
 
0.0005 
 
Analogy with americium, 
and neptunium; ICRP 
Pub. 67 (1993) 
 
Other actinides 
 
0.0005 (Parts 1,3) 
0.001 (Part 4) 
 
0.0005 
 
Analogy with americium 
and curium; ICRP Pub. 
67 (1993) and 71 (1995b). 
 
All other elements 
 
-- 
 
As in ICRP Pub. 30 
 
-- 
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Table 4.2.  Significance of changes in f1 values as judged by effect on 
dose estimates for workers.  Calculations are based on biokinetic 
models of ICRP Publication 68.  Only the f1 value is varied. 
 
 
f1 value 
 
Ratio of integrated doses A:B, where 
A is based on f1 from Pub 68 and B is 
based on f1 from Pub. 30 
 
 
Radionuclide 
 
ICRP 
 Pub. 30 
 
ICRP 
 Pub. 68 
 
Colon 
 
Red 
marrow 
 
Effective 
dose 
 
Co-60 (some 
compounds)  
 
0.3 
 
0.1 
 
0.77 
 
0.39 
 
0.49 
 
Ce-144 
 
0.0003 
 
0.0005 
 
1.0 
 
1.6 
 
1.0 
 
La-140 
 
0.001 
 
0.0005 
 
1.0 
 
1.0 
 
1.0 
 
Eu-152 
 
0.001 
 
0.0005 
 
1.0 
 
2.0 
 
1.1 
 
Th-232 (some 
compounds) 
 
0.0002 
 
0.0005 
 
1.5 
 
2.5 
 
2.5 
 
U-234 
 
0.05 
 
0.02 
 
0.59 
 
0.40 
 
0.42 
 
Pu-239 (some 
compounds) 
 
0.001 (Part 4) 
 
0.0005 
 
0.77 
 
0.50 
 
0.51 
 
Np-239 
 
0.001 (Part 4) 
 
0.0005 
 
1.0 
 
0.98 
 
1.0 
 
 As indicated in Table 4.2, the effect of f1 on dose coefficients depends strongly on the 
radionuclide and tissue, varying from virtually no effect to changes proportional to the changes in 
f1 values.  The effect on a dose coefficient depends on some combination of the following factors: 
the half-life of the radionuclide, the types and energies of the emitted radiations, the magnitude of 
the f1 value, and the systemic biokinetic model for the element.  When the f1 value is changed 
from one relatively small number to another (e.g., from 0.0003 to 0.0005 for 144Ce, 0.001 to 
0.0005 for 152Eu, or 0.001 to 0.0005 for 239Np), the estimated dose to the colon shows little 
change in many cases because the cumulative activity in the colon is nearly unchanged.  The 
derived effective dose will show little change in such cases if it is dominated by the dose to the 
colon.  Doses to systemic tissues (e.g., red marrow) often change nearly in proportion to f1, but 
this is not always the case.  In cases where the effective dose is determined largely by the dose to 
systemic tissues (e.g., 232Th, 234U, 239Pu), variation of f1 may result in a proportional change in the 
effective dose coefficient.  Depending on the residence time in systemic tissues, the effect on the 
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dose to systemic tissues may be diminished to some extent for radionuclides with highly 
penetrating radiations (e.g., 60Co) due to the contribution to dose from emissions from the 
intestinal contents.  For short-lived radionuclides such as 140La that are poorly absorbed and emit 
highly penetrating radiations, the dose to systemic tissues may be affected little by a variation in 
f1 because the dose may arise mainly from emissions from the contents of the gastrointestinal 
tract. 
Dose estimates for inhaled radionuclides address the gastrointestinal absorption of activity 
swallowed after removal from the respiratory tract by mucociliary transport.  For selected 
radionuclides, it is considered in both ICRP Publication 30 and Publication 68 that radionuclides 
cleared from the respiratory tract may be minor constituents of the inhaled particles and that 
absorption from the gastrointestinal tract may depend on dissolution of the particle matrix as well 
as the elemental form of the radionuclide.  The special f1 values for inhaled material used in ICRP 
Publication 68 are compared in Table 4.3 with values used in ICRP Publication 30.  Changes in f1 
for inhaled material were made for only three elements:  cobalt (from 0.05 for Class W to 0.1 for 
Type M), uranium (from 0.05 for Class D or W to 0.02 for Type F or M), and plutonium (from 
0.001for Class W to 0.0005 for Type M).  These modifications have only modest effects on dose 
estimates because they do not result in large changes in the total absorption of activity to blood 
from the respiratory and gastrointestinal tracts, and they have little effect on the estimate of 
cumulative activity in the contents of the gastrointestinal tract. 
 
4.4.  ICRP’s f1 values for members of the public 
In its series of documents on doses to the public from environmental intakes of 
radionuclides (ICRP, 1989, 1993, 1995a, 1995b, 1996), the ICRP summarized information on 
age-specific gastrointestinal uptake of 31 elements (listed earlier).  On the basis of these reviews, 
the following generic rules were applied in the assignment of age-specific f1 values to most of 
these elements, for the case of ingestion: 
1. The f1 value for adults is assigned to ages ≥1 y. 
2.  If f1 for adults is ≤0.001, then f1 for infants is 10 times the value for adults. 
3.  If f1 for adults is 0.01-0.5, then f1 for infants is 2 times the value for adults. 
4.  If f1 for adults is greater than 0.5, then complete absorption is assumed for the infant. 
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Table 4.3.  Comparison of f1 values applied in ICRP Publication 30 
and Publication 68 to inhaled material. 
 
 
Element 
 
ICRP Pub. 30 
 
ICRP Pub. 68 
 
Cobalt 
 
W: 0.05 
Y: 0.05 
 
M: 0.1 
S: 0.05 
 
Strontium 
 
D: 0.3 
Y: 0.01 
 
F: 0.3 
S: 0.01 
 
Molybdenum 
 
D: 0.8 
Y: 0.05 
 
F: 0.8 
S: 0.05 
 
Antimony 
 
D: 0.1 
W: 0.01 
 
F: 0.1 
M: 0.01 
 
Uranium 
 
D: 0.05 
W: 0.05 
Y: 0.002 
 
F: 0.02 
M: 0.02 
S: 0.002 
 
Plutonium 
 
W: 0.0001 (Part 1) 
W: 0.001 (Part 4) 
Y: 0.00001 
 
M: 0.0005 
S: 0.00001 
 
All other elements 
 
Same as for ingestion 
 
Same as for ingestion 
 
 
Rules 1-4 given above were not applied to ingested calcium, iron, cobalt, strontium, 
barium, lead, or radium (ICRP 1993, 1995a, 1995b).  For these elements, separate f1 values were 
assigned to infants, children of ages 1-15 y, and adults, respectively, based on indications that 
gastrointestinal absorption of these elements is elevated in young children and adolescents as 
well as infants.  For calcium and strontium, the f1 values applied to these three age groups are 
0.6, 0.4, and 0.3, respectively; for barium and radium, the values are 0.6, 0.3, and 0.2, 
respectively; for iron, the values are 0.6, 0.2, and 0.1, respectively; for cobalt, the values are 0.6, 
0.3, and 0.1, respectively; and for lead, the values are 0.6, 0.4, and 0.2, respectively. 
For elements not reviewed in the ICRP’s series on environmental intakes, f1 values for 
the adult are extended in ICRP Publication 72 (1996) to other age groups using Rules 1-4, with 
three exceptions:  for palladium, values 0.005 and 0.05 are applied to the adult and infant, 
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respectively; for beryllium, values 0.005 and 0.02 are applied; and for hafnium, values   0.002 
and 0.02 are applied. 
In ICRP Publication 72 (1996), two different sets of age-dependent f1 values are 
considered for radioisotopes of chromium.  Because chromium is not addressed in the ICRP 
documents on intake of radionuclides by members of the public, f1 values for ingestion of 
chromium by the adult were carried over from ICRP documents on occupational intakes and 
extended to younger age groups using the rules listed above.  The different f1 values for the 
adult, 0.1 and 0.01, reflect expected differences in absorption of hexavalent and trivalent 
compounds, respectively, of chromium encountered in the work place. 
Age-specific f1 values for polonium used in ICRP Publication 72 are taken from ICRP 
Publication 67 (1993) on environmental intake of radionuclides by members of the public and 
are based on data for ingestion of organically bound polonium.  The authors of ICRP Publication 
67 point out that gastrointestinal absorption of inorganic forms of polonium appears to be much 
lower than that of polonium that is biologically incorporated into food.  Because there are 
situations in which environmental polonium seems more likely to be in inorganic than organic 
form (for example, in tap water), separate sets of age-specific f1 values for inorganic and organic 
polonium were considered in Federal Guidance Report No. 13 (EPA, 1999).  For polonium 
ingested in inorganic form, the f1 value for the adult was taken as 0.1, the value applied by the 
ICRP to ingestion of polonium in the work place  (ICRP 1979, 1994a).  Based on Rules 1-4 
listed above, this value was applied to ages ≥1 y in Federal Guidance Report No. 13, and the 
value 0.2 was applied to infants. 
As described above for occupational intakes, the dosimetric scheme for members of the 
public includes the consideration that activity cleared from the respiratory tract may be present 
as minor constituents of the inhaled particles and that subsequent gastrointestinal absorption may 
depend on dissolution of the particle matrix (ICRP, 1996).  In ICRP Publication 72, the element-
specific f1 values applied to ingestion generally are applied to inhalation of Type F compounds. 
The most important exception is polonium, for which an f1 value of 0.5 is applied to ingestion in 
food and a value of 0.1 is applied to polonium inhaled as a Type F compound.  For inhaled 
material of Type M or Type S, a default f1 value of 0.1 or 0.01, respectively, is applied unless a 
lower f1 value for that absorption type, or a more soluble type, was used in the ICRP’s most 
recent document on occupational exposures (ICRP Publication 68, 1994a).  In the latter case, the 
lower f1 value is applied. 
The f1 values for “infant” apply to ages 0-100 days.  Biokinetic parameter values are 
assumed to vary with age up to age 20 y for most elements (e.g., iron, cesium, and iodine) but up 
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to age 25 y for some elements that deposit largely in the skeleton (e.g., calcium, radium, and 
plutonium).  Linear interpolation with age is used to vary parameter values between ages 100 d 
and 1 y, 1 y and 5 y, 5 y and 10 y, 10 y and 15 y, and 15 y and adult (defined either as 20 y or 25 
y, depending on the element).  For example, parameter values for age 3 y would fall midway 
between values for ages 1 y and 5 y. 
 
 4.5.  Sensitivity of dose coefficients for members of the public to f1 values 
The importance of assigning elevated f1 values to certain age groups and/or to 
environmental forms of radionuclides is illustrated in Table 4.4.  This table shows the extent to 
which ingestion dose coefficients for selected radionuclides and age groups are changed by 
changing f1 from the value assigned to the worker in ICRP Publication 30 to the value applied to 
members of the public.  For purposes of this sensitivity analysis, the biokinetic models applied in 
both cases are those for members of the public; only the f1 values are changed. 
As indicated earlier for workers, the effect of f1 on dose coefficients for members of the 
public depends strongly on the radionuclide and tissue, varying from virtually no effect to a 
change in proportion to the modification of f1.  When the f1 value is changed from one relatively 
small number to another (e.g., from 0.0003 to 0.0005 for 144Ce), the dose to the colon is not 
affected much because the cumulative activity in the colon is not changed much and is the main 
determinant of the dose to the colon.  If the effective dose is determined largely by the dose to 
the colon, then the effective dose may be changed little by a substantial change in f1 due to the 
small change in the colon dose.  Doses to systemic tissues (e.g., red marrow) change nearly in 
proportion to f1 in most cases.  Exceptions occur in cases where the dose to systemic tissues 
comes mainly from emissions from the gastrointestinal contents rather than absorbed activity. 
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Table 4.4.  Sensitivity of ingestion dose coefficients for members of the public to the f1 
value.  Dose coefficients for a given radionuclide and age at intake are calculated using 
alternate f1 values: (1) the value assigned to the worker in ICRP Publication 30, and (2) the 
value applied by the ICRP to members of the public.  In both calculations, the biokinetic 
model applied is that for members of the public. 
 
 
 
f1 value 
   
 Ratio of dose coefficient based 
on A to coefficient based on B 
 
  
    B: from ICRP 
Pub. 30 A: from ICRP series 
on intakes 
by public 
 Radio-
nuclide  
Age at 
intake 
 (worker)  
Colon 
 
 
 
Red 
marrow 
 
 
 
Effective 
dose 
 
Fe-59 
 
100 d 
 
0.6 
 
0.1 
 
0.9 
 
5.8 
 
2.9 
 
Fe-59 
 
15 y 
 
0.2 
 
0.1 
 
1.0 
 
1.9 
 
1.4 
 
Sr-90 
 
100 d 
 
0.6 
 
0.3 
 
0.8 
 
2.0 
 
1.9 
 
Sr-90 
 
15 y 
 
0.4 
 
0.3 
 
0.9 
 
1.3 
 
1.3 
 
Ce-144 
 
Adult 
 
0.0005 
 
0.0003 
 
1.0 
 
1.6 
 
1.0 
 
La-140 
 
Adult 
 
0.0005 
 
0.001 
 
1.0 
 
1.0 
 
1.0 
 
Po-210 
 
100 d 
 
1.0 
 
0.1 
 
5.1 
 
8.0 
 
7.9 
 
Po-210 
 
5 y 
 
0.5 
 
0.1 
 
3.3 
 
4.9 
 
4.9 
 
Po-210  
 
Adult 
 
0.5 
 
0.1 
 
3.4 
 
4.9 
 
4.9 
 
Pu-239 
 
100 d 
 
0.005 
 
0.001 
 
1.9 
 
5.0 
 
4.8 
 
Pu-239 
 
Adult 
 
0.0005 
 
0.001 
 
0.8 
 
0.5 
 
0.5 
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 5.  CHANGES IN SYSTEMIC BIOKINETIC 
 MODELS FOR RADIONUCLIDES 
 
 5.1. Background 
The biokinetic models of ICRP Publication 30 (1979, 1980, 1981, 1988a) generally are 
formulated as simple mathematical expressions and address only the initial distribution and net 
rate of decline of radionuclides in a few major organs.  Retention of a radionuclide in the whole 
body or specific organ typically is described in terms of 1-3 removal half-times, with multiple 
half-times representing retention in multiple hypothetical compartments.  With the exception of 
the biokinetic model for iodine, feedback of material from tissues to blood is not treated 
explicitly in Publication 30.  Rather, it is assumed that material leaving an organ moves directly 
to excreta. 
The ICRP’s series of documents on doses to members of the public (ICRP 1989, 1993, 
1995a, 1995b, 1996) include physiologically based, age-specific models for several elements, 
including calcium, strontium, barium, radium, iron, lead, thorium, uranium, neptunium, 
plutonium, americium, and curium.  These models depict feedback of material from organs to 
blood plasma, loss of material by specific excretion pathways, and certain physiological 
processes such as bone remodeling that are known to influence the biokinetics of radionuclides. 
Despite this trend toward physiological realism, most of the biokinetic models adopted 
by the ICRP for application to members of the public are similar in format to the models of ICRP 
Publication 30.  In particular, retention functions were applied to hydrogen (tritium), carbon, 
sulfur, cobalt, nickel, zinc, selenium, zirconium, niobium, molybdenum, technetium, ruthenium, 
silver, antimony, tellurium, cesium, cerium, and polonium. For some but not all elements, age-
specific parameter values (coefficients or half-times in the retention functions) were assigned to 
represent expected changes in distribution or retention of radionuclides during growth.  The 
models were modified to depict transfer of systemic activity to the urinary bladder or large 
intestine prior to excretion, which became a typical feature of ICRP biokinetic models after the 
introduction of explicit tissue weighting factors for the urinary bladder wall and colon in ICRP 
Publication 60 (1991). 
The model for iodine applied in the ICRP’s series on doses from environmental 
exposures (ICRP, 1989, 1993) is an age-specific version of the model for the adult originally 
applied in ICRP Publication 30 (Figure 5.1). That is the only systemic biokinetic in Publication 
30 in which recycling of material is depicted explicitly. 
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Figure 5.1.  Structure of the model for iodine used in ICRP 
Publication 30 (1979) and current ICRP documents. 
 
 
The physiologically based models applied by the ICRP to adult members of the public 
generally were carried over to ICRP Publication 68 (1994a), which updates effective dose 
coefficients for workers.  Exceptions are the models for curium and calcium, which appeared in 
ICRP Publication 71 (1995b), after Publication 68 had been completed.  Several non-
physiological models applied by the ICRP to adult members of the public were also carried over 
to ICRP Publication 68, including models for hydrogen (as tritiated water or organically bound 
tritium), zinc, selenium, niobium, zirconium, molybdenum, silver, antimony, tellurium, cerium, 
and polonium.  For the remaining elements, the models of ICRP Publication 30 were applied in 
ICRP Publication 68 but were modified to depict passage of excreted activity through the urinary 
bladder contents and the large intestine.  The generic form of these models (i.e., the implicit 
compartments and directions of flow of activity) is shown in Figure 5.2. 
Because most of the models of ICRP Publication 30 do not specify a division of excreted 
activity between urine and feces, element-specific ratios of urinary to fecal excretion were 
assigned in ICRP Publication 68 to elements other than hydrogen and carbon.  For tritium and 
radioisotopes of carbon, the dose is assumed to be uniform throughout the body, including the 
urinary bladder wall and upper and lower large intestines.  Table 5.1 lists the ICRP publications 
that introduced the biokinetic models applied in ICRP Publication 68 and the ratio of urinary to 
fecal excretion applied in Publication 68 to each element. 
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Figure 5.2.  Generic structure of most of the non-recycling 
biokinetic models currently used by the ICRP.  
 
 
 
The following sections discuss the primary changes in systemic biokinetic models 
between ICRP Publication 30 and ICRP Publication 68 and the significance of those changes 
with regard to estimates of cumulative activity in radiosensitive tissues. 
 
 5.2. Comparison of previous and updated models  
 for bone-volume seekers 
 
5.2.1.  ICRP Publication 30 model for alkaline earth elements 
The alkaline earth model introduced in ICRP Publication 20 (1973) is applied in ICRP 
Publication 30 (in modified form) to calcium and its physiological analogues, strontium, barium, 
and radium.  Compared with most of the biokinetic models traditionally used in radiation 
protection, the alkaline earth model of ICRP Publication 20 is unusual in its detail and in the 
association of some model parameters with physiological processes.  The formulation of the 
model is also unusual in that retention is expressed as a combination of power functions and 
exponential functions.  Whole-body retention R(t) at time t days after injection is described by 
the equation: 
R(t) = (1 - p)exp(-mt) + pEb(t + E)-b[Bexp(-rLt) + (1-B)exp(-srLt)]. 
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Table 5.1.  Sources of biokinetic models (original ICRP publication) and 
urinary to fecal ratios U:F used in ICRP Publication 68. 
____________________________________________________________________________________________ 
Element     ICRP Pub. / U:F     Element       ICRP Pub. / U:F         Element    ICRP Pub. / U:F 
____________________________________________________________________________________________ 
Hydrogen           56/a     Zirconium   67/5.0       Lutetium     30/1.0 
Beryllium      30/1.0    Niobium    56/5.0       Hafnium     30/1.0 
Carbon      30/a     Molybdenum  67/8.0       Tantalum     30/1.0 
Fluorine      30/1.0    Technetium   30/1.0       Tungsten     30/1.0 
Sodium      30/100    Ruthenium   30/4.0       Rhenium     30/1.0 
Magnesium     30/1.0    Rhodium    30/1.0       Osmium     30/1.0  
Aluminum     30/1.0    Palladium   30/1.0       Iridium      30/1.0  
Silicon       30/1.0    Silver     67/0.05      Platinum     30/1.0 
Phosphorous    30/9.0    Cadmium      30/1.0       Gold      30/b 
Sulfur       30/9.0    Indium     30/1.0       Mercury     30/1.0 
Chlorine      30/100    Tin      30/1.0       Thallium     30/1.0 
Potassium     30/1.0    Antimony    69/4.0       Lead      67/b   
Calcium      30/1.0    Tellurium    67/4.0        Bismuth     30/1.0 
Scandium     30/1.0    Iodine     56/b         Polonium     67/0.5 
Titanium      30/1.0    Cesium    30/4.0       Astatine     30/1.0 
Vanadium     30/1.0    Barium    67/b         Francium     30/1.0 
Chromium     30/1.0    Lanthanum   30/1.0       Radium     67/b   
Manganese     30/1.0    Cerium   67/0.11      Actinium     30/1.0  
Iron        69/b     Praseodymium 30/1.0       Thorium     69/b   
Cobalt       30/6.0    Neodymium   30/1.0         Protactinium   30/1.0 
Nickel       30/20    Promethium 30/1.0       Uranium     69/b   
Copper      30/1.0    Samarium   30/1.0       Neptunium    67/b   
Zinc        67/0.25   Europium   30/1.0         Plutonium    67/b   
Gallium      30/1.0    Gadolinium   30/1.0       Americium    67/b   
Germanium     30/c      Terbium    30/1.0       Curium    30/1.0 
Arsenic      30/1.0    Dysprosium   30/1.0       Berkelium    30/1.0 
Selenium      69/2.0    Holmium    30/1.0       Californium    30/1.0 
Bromine      30/1.0    Erbium    30/1.0       Einsteinium    30/1.0 
Rubidium      30/3.0    Thulium    30/1.0       Fermium     30/1.0 
Strontium        67/b          Ytterbium   30/1.0         Mendelevium   30/1.0 
Yttrium      30/1.0          
____________________________________________________________________________________________ 
 aExcretion pathways are not considered.  
bExcretion pathways included explicitly in the recommended biokinetic model. 
cExcretion only in urine for activity deposited in kidney.  Ratio of 1.0 used for activity in other tissues. 
dExcretion only in urine.  
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Some of the parameters are element dependent, and some are related to processes rather than 
specific elements.  The parameter L is the rate of apposition and resorption in compact bone, s is 
the ratio of turnover rates of trabecular and compact bone, B is the fraction of bone volume 
activity deposited in compact bone, and r is an element-specific factor that corrects for 
redeposition of activity in new bone at sites of resorption long after injection.  The power 
function slope, b, is related to diffusion of activity from bone but is element specific.  The 
element-specific parameter values E (a small time related to the turnover of an initial pool), m 
(the rate constant of a small early exponential in R), and p (the fraction of R not in the early 
exponential) are not clearly related to processes. 
 
5.2.2. ICRP Publication 30 model for lead 
The biokinetic model for lead recommended in ICRP Publication 30 is typical of the 
models used in that document.  Based on experimental data on dogs, it is assumed that 55% of 
lead leaving the transfer compartment (blood) deposits in the skeleton, 25% in the liver, and 2% 
in the kidneys.  The remaining 18% is uniformly distributed throughout the rest of the body.  The 
residence time of lead in blood is based on the generic half-time of 0.25 d used for most elements 
in ICRP Publication 30.  Each of the source organs (skeleton, liver, kidneys, other) consists of 
three hypothetical compartments corresponding to biological half-times of 12, 180, and 10,000 d. 
The first two half-times are derived from data for dogs, and the third (10,000 d) is based on 
indications of a long-term retention component for lead in humans.  The relative fractions 
assigned to short-, intermediate-, and long-term retention in the skeleton are 0.6, 0.2, and 0.2, 
respectively, and those for other organs are 0.8, 0.18, and 0.02, respectively. On the basis of 
findings that lead can substitute for calcium in bone mineral, the assumption is made that 
relatively long-lived isotopes of lead such as 210Pb are uniformly distributed throughout the 
volume of mineral bone at all times after deposition in the skeleton.  Isotopes of lead with half-
lives less than 15 d are assigned to bone surfaces. 
 
5.2.3. ICRP Publication 30 model for uranium 
The biokinetic model for uranium introduced in ICRP Publication 30 was based on 
limited data on human subjects (including environmental data that now appear to be in error), 
occupational data on one subject, and experimental data involving terminally ill subjects.  The 
body is divided into a transfer compartment (blood) and three repositories:  mineral bone, 
kidneys, and all other tissue.  Of uranium entering the transfer compartment, fractions 0.2 and 
0.023 are assigned to mineral bone and removed with half-times of 20 and 5,000 d, respectively; 
fractions 0.12 and 0.00052 are assigned to the kidneys and removed with half-times of 6 and 
1500 d, respectively; and fractions 0.12 and 0.00052 are assumed to be uniformly distributed 
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among all other tissues of the body and removed with half-lives of 6 and 1500 d, respectively.  
The remainder is assigned to excretion.  Long-lived uranium isotopes such as 234U, 235U, and 
238U are assumed to be distributed uniformly throughout mineral bone at all times following 
deposition in the skeleton, but short-lived isotopes are assigned to bone surfaces.  
 
5.2.4. Updated models for the alkaline earths, lead, and uranium 
The ICRP’s alkaline earth model was updated in the ICRP series on doses to members of 
the public.  The structure of the updated model (Figure 5.3) was also applied in that series to lead 
and uranium, two elements whose skeletal behavior is broadly similar to that of calcium (ICRP, 
1993, 1995a, 1995b). 
 
 
 
 
Figure 5.3.  ICRP’s generic model structure for calcium-like elements, introduced 
in ICRP Publication 67 (1993) and applied in that document or subsequent ICRP 
documents to calcium, strontium, barium, radium, lead, and uranium. 
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 In the updated model for the alkaline earth elements and related elements, plasma is 
treated as a uniformly mixed pool.  A compartment representing red blood cells is included for 
application to lead and uranium but is not used in the models for the alkaline earth elements. Soft 
tissues (excluding liver and kidneys, when these organs are treated explicitly) are divided into 
compartments corresponding to fast, intermediate, and slow return of activity to plasma 
(compartments ST0, ST1, and ST2, respectively).  The liver and kidneys are not assigned 
separate parameter values for calcium, strontium, and barium, but liver is assumed to have 
elevated uptake and retention of radium, and liver and kidneys are both important components of 
the biokinetic models for lead and uranium.  As in the alkaline earth model described in ICRP 
Publication 20 (ICRP 1973), bone is divided into cortical surface, cortical volume, trabecular 
surface, and trabecular volume, and rapidly exchangeable activity in bone is assumed to reside 
on bone surfaces.  The model of ICRP Publication 20 has a power-function component 
accounting for most of the biological removal from bone during the first few months after 
injection (ICRP,1973).  In the updated alkaline earth model, this intermediate-term removal from 
bone is treated as first-order removal from “exchangeable” bone volume pools.  That is, cortical 
and trabecular bone volume are each divided into “exchangeable” and “non-exchangeable 
pools”. Activity moving from bone surfaces to bone volume enters the exchangeable pool and 
leaves this pool with an element-specific half-time, on the order of a few weeks or months.  Part 
of the activity leaving exchangeable bone volume returns to rapidly exchanging bone surfaces 
and part goes to non-exchangeable bone volume, from which it is removed to plasma at the rate 
of bone turnover.  Excretion of the alkaline earth elements and uranium is assumed to occur only 
in urine and feces, but excretion via sweat and hair is also considered in the model for lead. 
As a rule, the updated models for bone-volume seekers were based on a larger set of 
information than was used in the construction of the models of ICRP Publication 30.  For 
example, parameter values for lead were derived from information from lead tracer studies on 
healthy adult human volunteers; autopsy data for environmentally exposed subjects; lead balance 
studies on adult human subjects; bioassay and autopsy data on lead workers; studies of radiolead 
in baboons, monkeys, beagles, and other laboratory animals; and comparisons of lead and 
alkaline earths in bone. 
 
5.2.5. Comparison of predictions of updated and previous models 
Cumulative activities in tissues as predicted by the previous and updated models are 
compared in Table 5.2 for selected bone-volume-seeking radionuclides.  These comparisons 
address only the parent radionuclides.  Updated models of chain members produced in the body 
are addressed later. 
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Table 5.2.  For selected bone-volume-seeking radionuclides, comparison of 50-y integrated 
activities in tissues of the adult as predicted by the models of ICRP Publication 30 and 
Publication 68.  It is assumed that 1 Bq is injected into blood at time zero. 
 
 
Ratio of predicted integrated activity 
following injection into blood 
ICRP 68 : ICRP 30 
 
 
 
Radio-
nuclide 
 
 
 
 
Half-life  
 
Blood 
 
Soft 
tissue  
 
Compact 
bone  
 
Trabecular 
bone  
 
Whole 
body 
 
Sr-89 
 
52 d 
 
1.5 
 
0.8 
 
0.9 
 
1.4 
 
1.0 
 
Sr-90 
 
28.1 y 
 
3.6 
 
0.5 
 
1.1  
 
1.0 
 
1.0 
 
Ba-133 
 
10.7 y 
 
1.5 
 
1.2 
 
1.3 
 
1.7 
 
1.4 
 
Ba-140 
 
12.8 d 
 
1.4 
 
0.4 
 
2.0 
 
2.9 
 
1.6 
 
Ra-223 
 
11.4 d 
 
1.5 
 
0.4 
 
1.7 
 
2.3 
 
1.4 
 
Ra-224 
 
3.64 d 
 
1.5 
 
0.4 
 
1.5 
 
1.9 
 
1.5 
 
Ra-226 
 
1602 y 
 
1.5 
 
0.5 
 
1.8 
 
1.5 
 
1.5 
 
Pb-210 
 
22.3 y 
 
 71 
 
1.1 
 
1.2 
 
1.4 
 
1.0 
 
Pb-212 
 
10.64 h 
 
1.5 
 
0.8 
 
0.8 
 
0.5 
 
1.0 
 
U-234 
 
2.445E5 y 
 
0.3 
 
17 
 
1.3 
 
1.5 
 
1.8 
 
U-237 
 
6.75 d 
 
0.2 
 
1.3 
 
0.6 
 
0.8 
 
0.8 
 
 
 Inventories of radium in skeleton and soft tissues as a function of time after intravenous 
injection as predicted by the previous and current models are compared in Figure 5.4.  The 
updated model predicts a higher skeletal content at all times after injection and a lower content in 
soft tissues for the first few years after injection.  For times beyond five years after injection, the 
two models yield similar predictions of the radium content in soft tissues. 
Differences in model predictions of the cumulative activity of lead in the skeleton 
generally are greater for short-lived isotopes such as 212Pb than relatively long-lived isotopes 
such as 210Pb (Table 5.2).  This is because the previous and updated models for lead predict 
much different patterns of early uptake and retention of lead but reasonably similar patterns of 
long-term skeletal retention.  The “one-directional”, exponential models used in ICRP 
Publication 30 often were calibrated to yield a reasonable long-term distribution of an element.  
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Figure 5.4.  Time-dependent inventories of radium in tissues as 
predicted by the previous and updated ICRP models, for the case of 
injection of radium into blood at time zero. 
 
 Because the models of ICRP Publication 30 generally did not address recycling of 
activity, the maximal contents of organs were depicted as occurring soon after introduction of 
activity to blood, which is often not the case.  In the apparently more realistic representation of 
lead kinetics in the updated model, much of the lead reaching blood is taken up by red blood 
cells and transferred over a period of weeks to longer-term storage in the skeleton. 
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An important feature of the physiologically based models used in recent ICRP documents 
is that the models link excretion with interchange of activity among body tissues.  Thus, the 
same model can be used both for interpretation of bioassay and for radiation dosimetry. 
 
 5.3. Comparison of previous and updated models for bone-surface seekers 
 
5.3.1. ICRP Publication 30 models for plutonium and related elements 
The model initially applied in ICRP Publication 30 (Part 1, 1979; Part 2, 1980; Part 3, 
1981) to plutonium as well as to actinium, neptunium, and transplutonium elements was 
introduced in ICRP Publication 19 (1972).  In the implementation of that model in ICRP 
Publication 30, it is assumed that 45% of activity leaving the transfer compartment deposits on 
bone surfaces, from which it is removed directly to excretion with half-time of 100 y; 45% 
deposits in liver and is removed directly to excretion with half-time of 40 y; almost 10% goes 
directly to excretion, and 0.035% deposits in the testes and 0.011% in the ovaries, where it is 
permanently retained.  Parameter values were based on consideration of data for humans as well 
as for a variety of animal species.  The biological half-time in liver was based mainly on an 
assumed relationship between body weight and hepatic retention.  The half-time in the skeleton 
was based mainly on an assumed relationship between life span and skeletal retention. 
 
Figure 5.5.  Model for plutonium and related elements used in Parts 
1-3 of ICRP Publication 30 (1979, 1980, 1981).  
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The model for plutonium and related elements was modified in ICRP Publication 48 
(1986), where some element-specific parameter values were introduced.  The modified models 
were used in Part 4 of ICRP Publication 30, which superseded portions of Parts 1-3.  For 
plutonium, americium, and curium, the assigned removal half-time from skeleton was reduced to 
50 y and that from liver was reduced to 20 y.  These same removal half-times are assigned to 
other elements addressed in ICRP Publication 48, but the initial division of activity between 
bone surfaces and liver is assumed to be 75% / 15% for neptunium and 65% / 25% for 
berkelium, californium, einsteinium, fermium, and mendelevium.  The remaining actinide 
elements were not addressed in ICRP Publication 48. 
 
5.3.2. ICRP Publication 30 model for thorium 
The biokinetic model for thorium used in ICRP Publication 30 was developed separately 
from the model for plutonium and related elements.  On the basis of observations of the fate of 
228Th in beagles, it is assumed that thorium leaves the transfer compartment with a half-time of 
0.5 d, with 70% depositing on bone surfaces, 4% depositing in the liver, 16% depositing in other 
soft tissues, and 10% lost in excreta.  Thorium is removed from bone surfaces to excretion with a 
biological half-time of 8000 d and from liver and other soft tissues to excretion with a biological 
half-time of 700 d.  The assumption that skeletal deposits remain on bone surfaces until removed 
to excretion is generally applied in ICRP Publication 30 to actinide elements, with the exception 
of long-lived isotopes of uranium. 
 
5.3.3. Updated models for thorium, plutonium, and related elements 
In the ICRP documents addressing environmental exposures to members of the public, a 
generic model structure was applied to the “bone-surface-seeking” actinide elements thorium, 
neptunium, plutonium, americium, and curium (Figure 5.6).  The updated models for these 
elements, excluding curium, were applied to the worker in ICRP Publication 68.  The updated 
model for curium was adopted after the completion of ICRP Publication 68. 
While the model structure for these five elements is generic, many of the transfer 
coefficients are not.  Some transfer coefficients associated with compartments within the 
skeleton are expressed in terms of bone remodeling rates and thus are independent of the 
bone-surface seeker.  Nevertheless, element-specific transfer coefficients are required for most of 
the paths shown in Figure 5.6.  For the most part, the element-specific parameter values were 
chosen to reproduce data on human subjects, but it was often necessary to supplement data on 
man with information derived from studies of laboratory animals. 
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Figure 5.6. Generic model structure currently applied by the ICRP to 
plutonium and related elements (ICRP 1993, 1994a, 1995a, 1995b). 
 
 
The generic model structure divides systemic tissues and fluids into six main parts, 
corresponding to blood, skeleton, liver, kidneys, gonad, and other soft tissues.  Blood and gonads 
are each treated as uniformly mixed pools, but each of the other major divisions of the model is 
further divided into a minimal number of compartments needed to explain available biokinetic 
data on thorium and chemically similar elements.  The skeleton is divided into cortical and 
trabecular fractions, and each of these is subdivided into fractions associated with bone surface, 
bone volume, and bone marrow.  Activity entering the skeleton is assigned to compartments of 
bone surface but is assumed to transfer gradually to bone marrow by bone resorption or to 
compartments of bone volume by bone formation.  Activity in bone volume compartments 
transfers gradually to bone marrow compartments by resorption.  Activity moves from bone 
marrow compartments to blood over a few months and is redistributed in the same pattern as the 
original input to blood.  Liver is divided into two compartments representing short-term and 
relatively long-term retention.  Activity enters the short-term liver compartment and 
subsequently is divided among blood, the long-term liver compartment, and the contents of the 
gastrointestinal tract.  Activity leaving the long-term liver compartment is assigned to blood.  
The kidneys are divided into two compartments, one that loses activity to urine and another that 
returns activity to blood.  The urinary bladder content is considered as a separate pool that 
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receives all material destined for urinary excretion.  Other soft tissues are divided into three 
pools corresponding to rapid (hours or days), intermediate (weeks or months), and slow (years) 
turnover.  The rapid-turnover pool, which includes extracellular fluids, exchanges activity with 
blood. 
 
5.3.4. Comparison of predictions of updated and previous models 
Cumulative activities in tissues as predicted by the previous and updated models are 
compared in Table 5.3 for selected bone-surface-seeking radionuclides.  These comparisons 
address only the parent radionuclides. The extent of differences in predictions of the old and new 
models varies with the element and tissue as well as the half-life of the isotope.  For example, the 
old and new models for thorium predict similar initial uptake by the liver, but the new model 
depicts recycling from bone and other tissues to liver, with the result that differences in 
predictions of cumulative activity in the liver are large for the long-lived thorium isotope 232Th 
and small for the short-lived isotope 234Th.  In most cases, the new models for bone-surface 
seekers do not predict appreciably lower activity on bone surfaces than the older models despite 
consideration of gradual burial of activity in bone surface in the new models, because the new 
models also depict gradual movement of activity from liver to bone surfaces, which offsets some 
of the effects of burial in bone.  For isotopes of neptunium, however, predicted activity on bone 
surface is decreased substantially because there is little initial activity in the liver to replenish the 
bone-surface activity buried in bone volume. 
Time-dependent inventories of thorium in different tissues, as predicted by the old and 
new models for the case of injection into blood at time zero, are compared in Figure 5.7.  The 
updated model predicts longer retention in the skeleton, liver, and other soft tissues, and 
consequently longer retention in the total body of the adult.  For example, the model of 
Publication 30 predicts that ~75% of long-lived thorium injected into blood at time zero will be 
excreted in 10,000 days, compared with a prediction of ~30% based on the updated model. 
In Table 5.4, comparisons are made of the updated and previous models as predictors of 
the 50-y cumulative activity of 232Th and 228Ra in selected organs of an acutely exposed adult.  
Three types of acute intake are considered:  injection of 232Th into blood, ingestion of 232Th, and 
inhalation of a moderately soluble form of 232Th (Type M or class W, respectively, in the 
updated and previous respiratory tract models).  The assumption of independent kinetics of 
decay chain members is used in conjunction with the updated systemic model (as in ICRP 
Publication 68), and the assumption of shared kinetics is used with the model of ICRP 
Publication 30. 
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Table 5.3.  For selected bone-surface-seeking radionuclides, comparison of 50-y integrated 
activities in tissues of the adult as predicted by the models of ICRP Publication 30 and 
Publication 68.  It is assumed that 1 Bq is injected into blood at time zero. 
 
 
Ratio of predicted integrated activity 
for injection of 1 Bq into blood 
ICRP 68 : ICRP 30 
 
 
 
 
 
Radio-
nuclide 
 
 
 
 
 
Half-life 
 
 
Blood 
 
 
Liver 
 
 
Other  
 
Bone 
surface  
 
Whole 
body 
 
Th-232 
 
1.4E10 y 
 
2.5 
 
11 
 
7.7 
 
1.4 
 
2.0 
 
Th-234 
 
24.1 d 
 
0.7 
 
1.2 
 
1.1 
 
1.0 
 
1.0 
 
Np-237 
 
2.1E6 y 
 
3.2 
 
0.18 
 
a 
 
0.4 
 
0.5 
 
Np-239 
 
2.355 d 
 
1.2 
 
0.6 
 
a 
 
0.5 
 
0.8 
 
Pu-237 
 
45.3 d 
 
4.2 
 
0.7 
 
a 
 
1.1 
 
1.1 
 
Pu-239 
 
24065 y 
 
14 
 
1.1 
 
a 
 
0.9 
 
1.3 
 
Am-240 
 
50.8 h 
 
0.1 
 
1.1 
 
a 
 
0.7 
 
1.0 
 
Am-241 
 
432.2 y 
 
0.6 
 
0.3 
 
a 
 
1.0 
 
1.0 
aOther soft tissue not included in the model of ICRP Publication 30. 
 
Differences between the old and new models for bone-surface-seeking radionuclides 
generally are more important for applications involving interpretation of bioassay data than for 
derivation of dose coefficients.  For example, the rate of urinary excretion of plutonium at times 
remote from injection as predicted by the updated model for plutonium is an order-of-magnitude 
higher than predicted by the bioassay model for plutonium given in ICRP Publication 54 
(1988b).  This will result in large differences in dose estimates based on urinary plutonium 
measured long after exposure. 
 
 5.4. Comparison of previous and updated models for iron 
 
5.4.1. ICRP Publication 30 model for iron 
The biokinetic model for iron recommended in ICRP Publication 30 was based on the 
equilibrium distribution of iron in the human body as indicated by Reference Man data (ICRP, 
1975).  It is assumed that 8% of iron leaving the transfer compartment is deposited in the liver 
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Figure 5.7.  Time-dependent inventories of thorium in tissues 
as predicted by the previous and updated ICRP models, for the 
case of injection of thorium into blood at time zero. 
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and 1.3% is deposited in the spleen, and the remainder is uniformly distributed throughout all 
other tissues of the body.  The removal half-time from all tissues is assumed to be 2000 d. 
 
5.4.2. Updated model for iron 
A physiologically based model for iron was introduced in ICRP Publication 69 (1995a).  
This updated model was applied to the worker in ICRP Publication 68. This recycling model 
describes three main aspects of iron metabolism:  (1) the hemoglobin cycle, including uptake of 
transferrin-bound iron by the erythroid marrow for incorporation into hemoglobin, subsequent 
appearance of iron in red blood cells, uptake of old and damaged red blood cells by the 
reticuloendothelial system, and eventual return of iron to plasma; (2) removal of 
transferrin-bound iron from plasma to the extravascular spaces and return to plasma via the 
lymphatic system; and (3) uptake and retention of iron by the parenchymal tissues.  The soft 
tissues include a pool of extravascular iron that exchanges rapidly with plasma iron.  Storage 
iron is divided among liver, spleen, red marrow, and other soft tissues. Destruction of red blood 
cells is viewed as occurring in the red marrow.  The liver is viewed as consisting of two pools:  a 
transit pool representing parenchymal tissues that exchange iron with plasma, and a storage pool 
associated with the reticuloendothelial system.  Excretion of iron is depicted as occurring 
through exfoliation of skin, losses of plasma iron in urine, and leakage of red blood cells into the 
intestines and subsequent removal in feces. 
 
5.4.3. Comparison of predictions of updated and previous models 
Cumulative activities in tissues as predicted by the previous and updated models for iron 
are compared in Table 5.4 for 52Fe, 55Fe, 59Fe, and 60Fe.  These comparisons address only the 
parent radionuclide.  
Parameter values for the iron model in ICRP Publication 30 were designed to reproduce 
the equilibrium distribution of iron in selected tissues.  The updated model was designed to 
approximate the iron inventories of blood and tissues as a function of time after injection of iron 
into blood.  It is not surprising, therefore, that the extent of differences in model predictions for a 
given tissue depend on the half-life of the iron isotope. For all isotopes, reasonable agreement 
between the two models is obtained for cumulative activity in the total body.  Because the 
previous model does not depict recycling of iron to blood, it underestimates the blood content at 
times remote from injection. For the spleen, the previous model predicts a much higher 
cumulative activity than does the updated model for short-lived isotopes but a much lower 
cumulative activity for long-lived isotopes.  For the liver, the updated model predicts cumulative 
activities that are 40-60% lower than those predicted by the previous model. 
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Table 5.4.  For radioisotopes of iron, comparison of 50-y integrated activities in tissues of 
the adult as predicted by the models of ICRP Publication 30 and Publication 68.  It is 
assumed that 1 Bq is injected into blood at time zero. 
 
 
Ratio of predicted integrated activity 
for injection of 1 Bq into blood 
ICRP 68 : ICRP 30 
 
 
 
 
 
Radio-
nuclide 
 
 
 
 
 
Half-life 
 
 
Blood 
 
 
Liver 
 
 
Spleen 
 
Remaining 
tissuesa 
 
Whole 
body 
 
Fe-52 
 
8.275 h 
 
0.7 
 
2.6 
 
0.07 
 
1.1 
 
1.0 
 
Fe-55 
 
2.7 y 
 
1500 
 
1.9 
 
4.4 
 
0.4 
 
1.2 
 
Fe-59 
 
44.53 y 
 
120 
 
2.1 
 
1.0 
 
0.2 
 
1.0 
 
Fe-60 
 
1E5 y 
 
5500 
 
2.5 
 
7.7 
 
0.7 
 
1.6 
aRed marrow is considered as a separate source organ in the updated model but not the previous model.  
For the present comparison, red marrow is considered part of remaining tissues.  
 
 
 5.5. Examples of other model updates for workers  
 
5.5.1. Hydrogen 
ICRP Publication 68 provides biokinetic models for both tritiated water and organically 
bound tritium, while Publication 30 provides a model only for tritiated water.  According to the 
model of Publication 30, tritiated water is uniformly distributed in the body and removed with a 
half-life of 10 d.  In Publication 68, half-times of 10 d (97%) and 40 d (3%) are assumed for 
tritiated water.  The same half-times are used in Publication 68 for organically bound tritium, but 
each half-time is assumed to be associated with 50% of the absorbed amount. 
Little difference in predictions of the cumulative activity in the body arises from the two 
slightly different models for tritiated water.  The model of Publication 68 for organically bound 
tritium yields an estimated cumulative activity in the total body roughly 2.5 times greater than 
that produced by the model for tritiated water. 
 
5.5.2. Sulfur 
The systemic model for sulfur in ICRP Publication 30 addresses only inorganic sulfur.  
According to the model, fractions 0.15 and 0.05 of sulfur leaving the transfer compartment are 
distributed uniformly throughout the body and retained with half-times of 20 and 2000 d, 
 57
 
respectively.  The remaining fraction, 0.8, goes directly to excreta.  A similar model, with added 
excretion pathways, was applied in ICRP Publication 68 to inorganic sulfur. 
An alternate model was applied in ICRP Publication 68 to organic sulfur.  According to 
that model, all of the organically bound sulfur leaving blood is uniformly distributed in the body 
and removed with a half-time of 140 d.  Compared with the model for inorganic sulfur, this 
model gives an eightfold higher cumulative total-body activity for 35S. 
 
5.5.3. Selenium 
In the model for selenium in ICRP Publication 30, liver, kidneys, spleen, pancreas, and 
all other tissues receive 15%, 5%, 1%, 0.5%, and 78.5%, respectively, of activity leaving the 
transfer compartment.  For any tissue, fractions 0.1, 0.4, and 0.5 are assumed to be retained with 
biological half-times of 3, 30, and 150 d, respectively. 
The model for selenium used in ICRP Publication 68 (1994a) was developed for 
application to adult members of the public (ICRP, 1995a).  According to that model, the liver, 
kidneys, spleen, pancreas, testes, ovaries, and remaining tissues receive 25%, 10%, 1%, 0.5%, 
0.1%, 0.02%, and 63.4%, respectively, of selenium leaving blood.  For any tissue, fractions 0.1, 
0.4, and 0.5 are retained with biological half-times of 3, 30, and 200 d, respectively. 
The modifications of the selenium model make little difference in predictions of 
cumulative activity for relatively short-lived isotopes.  For long-lived isotopes, the model 
increases the predicted cumulative activity in the liver and kidneys by more than a factor of 2 
and in the total body by about a factor of 1.3.  
 
5.5.4. Zirconium 
The retention model for zirconium given in ICRP Publication 30 includes two removal 
half-times: 7 d (50%) and 8000 d (50%).  The long-term component is associated with bone and 
the short-term component with all other tissues.  Skeletal zirconium is assigned to bone surfaces. 
The model of Publication 68 is similar, but the removal half-time from bone is assumed to be 
10,000 d rather than 8,000 d.  This minor change stems from a generic assumption first applied 
in ICRP Publication 67 (1993) to bone-seeking radionuclides whose biokinetic models are the 
traditional “one-directional” retention functions.  As with most elements addressed in ICRP 
Publication 68, the model of Publication 30 was also modified to include specific urinary and 
fecal excretion fractions and passage of excreted activity through the urinary bladder and large 
intestine.  The modifications yield only trivial changes in predicted cumulative activities and 
tissue doses from important isotopes of zirconium. 
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5.5.5. Molybdenum 
The systemic model for molybdenum adopted in ICRP Publication 30 is a two-
component retention function with half-times of 1 d (10%) and 50 d (10%). The model of 
Publication 68, introduced in ICRP Publication 67 (1993), assumes that 10% of activity leaving 
blood is deposited in the skeleton, from which is removed with a half-time of 10,000 d.  The 
remaining activity is distributed to liver (25%), kidneys (5%), and all other tissues (60%).  For 
tissues other than skeleton, fractions 0.1 and 0.9 are assumed to be removed with half-times of 
1 and 50 d, respectively.  Differences in predictions of the two models are modest for short-lived 
isotopes of molybdenum but make a substantial difference in the predicted cumulative activity in 
bone and total-body for the long-lived isotope 93M (Table 5.5). 
 
5.5.6. Silver 
In the model for silver given in ICRP Publication 30, 80% of activity leaving the transfer 
compartment is assigned to liver and 20% is assigned to other tissues.  For each pool, fractions 
0.1 and 0.9 are assigned biological half-times of 3.5 d and 50 d, respectively.  The model was 
modified in ICRP Publication 67 (1993) to depict greater deposition in tissues other than liver 
and a small retention component with a long half-time.  In the updated model, 50% of activity 
leaving blood is assigned to liver and 50% to other tissues.  For each pool, fractions 0.1, 0.8, and 
0.1 of deposited activity are assigned biological half-times of 3.5 d, 50 d, and 500 d, 
respectively. The effects of the updated model on predictions of cumulative activity in liver, 
other tissues, and total body are indicated in Table 5.6 for three isotopes of silver with much 
different half-lives. 
 
Table 5.5.  For radioisotopes of molybdenum, comparison of 50-y integrated activities in 
tissues of the adult as predicted by the models of ICRP Publication 30 and Publication 68.  
It is assumed that 1 Bq is injected into blood at time zero. 
 
 
Ratio of predicted integrated activity 
for injection of 1 Bq into blood 
ICRP 68 : ICRP 30 
 
 
 
 
Radio- 
nuclide 
 
 
 
 
Half-
life 
 
Cortical 
bone 
 
Trabecular 
bone 
 
 
Liver 
 
 
Kidney 
 
Other 
tissue 
 
Total 
body 
 
Mo-93 
 
3500 y 
 
170 
 
42 
 
0.8 
 
1.0 
 
1.2 
 
17 
 
Mo-99 
 
66.0 h 
 
0.8 
 
0.8 
 
0.8 
 
1.0 
 
1.2 
 
1.0 
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Table 5.6.  For radioisotopes of silver, comparison of 50-y integrated activities in tissues of 
the adult as predicted by the models of ICRP Publication 30 and Publication 68.  It is 
assumed that 1 Bq is injected into blood at time zero. 
 
 
Ratio of predicted integrated activity 
for injection of 1 Bq into blood 
ICRP 68 : ICRP 30 
 
 
 
Radio-
nuclide 
 
 
 
 
Half-life  Liver 
 
Other tissue 
 
Total body 
 
Ag-108m 
 
127 y 
 
0.8 
 
0.2 
 
0.5 
 
Ag-110m 
 
249.9 d 
 
0.8 
 
33 
 
1.3 
 
Ag-111 
 
7.45 d 
 
0.6 
 
2.5 
 
1.0 
 
 
 
5.5.7. Antimony 
In the model for antimony given in ICRP Publication 30, 20% of activity leaving the 
transfer compartment is assigned to excreta, 20% to bone surface, 10% to liver, and 50% to all 
other tissues.  For any tissue, fractions 0.95 and 0.05 are assigned biological half-times of 5 and 
100 d, respectively. 
The model for antimony was updated in ICRP Publication 69 (1995a), and the updated 
model was applied in ICRP Publication 68.  In the revised model, 20% of antimony leaving 
blood is assigned to excreta, 40% to bone surface, 5% to liver, and 35% to all other tissues.  For 
any tissue, fractions 0.85, 0.1, and 0.05 are assigned biological half-times of 5, 100, and 5000 d, 
respectively. 
The effects of the updated model on predictions of cumulative activity in various tissues 
are indicated in Table 5.7 for three isotopes of antimony with much different half-lives.  
Compared with the previous model, the updated model predicts substantially higher cumulative 
activity in most tissues, particularly bone, for relatively long-lived isotopes. 
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Table 5.7.  For radioisotopes of antimony, comparison of 50-y integrated activities in 
tissues of the adult as predicted by the models of ICRP Publication 30 and Publication 68.  
It is assumed that 1 Bq is injected into blood at time zero. 
 
 
Ratio of predicted integrated activity 
for injection of 1 Bq into blood 
ICRP 68 : ICRP 30 
 
 
 
 
Radio- 
nuclide 
 
 
 
 
 
Half-life 
 
Cortical 
bone 
 
Trabecular 
bone 
 
 
Liver 
 
Other 
tissue 
 
 
Total body 
 
Sb-124 
 
60.2 d 
 
3.4 
 
3.4 
 
0.9 
 
1.2 
 
1.7 
 
Sb-125 
 
2.77 y 
 
12 
 
12 
 
3.0 
 
4.2 
 
5.8 
 
Sb-126 
 
12.4 d 
 
2.4 
 
2.4 
 
0.6 
 
0.8 
 
1.2 
 
 
5.5.8. Tellurium 
In the model for tellurium given in ICRP Publication 30, 50% of tellurium entering the 
transfer compartment is assigned to excreta, 25% to mineral bone, and 25% to remaining tissues. 
Retention half-times assigned to bone and other tissues are 5000 d and 20 d, respectively.  The 
clearance half-time from the transfer compartment is assumed to be 0.8 d, rather than the default 
half-time of 0.25 d generally used in ICRP Publication 30. 
The model for tellurium was updated in ICRP Publication 67 (1993), and the updated 
model was applied in ICRP Publication 68.  In the revised version of the model, 50% of 
tellurium entering the blood is assigned to excreta, 25% to mineral bone, 0.2% to the thyroid, 
2.3% to the kidneys, and 22.5% to remaining tissues.  Retention half-times assigned to bone and 
other tissues are 10,000 d and 20 d, respectively.  The clearance half-time from blood is assumed 
to be 0.8 d.  For important isotopes of tellurium, the updated model yields relatively modest 
changes in estimates of cumulative activity in tissues. 
 
5.5.9. Polonium 
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In ICRP Publication 30, percentages 10%, 10%, 10%, and 70% of polonium leaving the 
transfer compartment are assigned to liver, kidney, spleen, and other tissues, respectively.  In 
Publication 68, 30%, 10%, 5%, 10%, and 45% are assigned to liver, kidneys, spleen, red bone 
marrow, and all other tissues, respectively.  In both models, a retention half-time of 50 d is 
assigned to all tissues.  For 210Po, these changes result in a threefold reduction in the estimated 
cumulative activity in liver and a twofold increase in the estimate for spleen.  Because the red 
marrow is an explicitly identified source organ in the updated model and is assigned a deposition 
fraction much greater than its mass fraction, the updated model yields a sixfold higher estimate 
of integrated dose to red marrow than the previous model. 
 
 5.6.  Changes in treatment of systemic kinetics of decay chain members formed in vivo 
 
5.6.1.  Different approaches used by the ICRP 
In ICRP Publication 30, decay chain members produced in the body generally are 
assigned the biokinetic model of the parent radionuclide, which is referred to as the assumption 
of “shared kinetics”.  Exceptions are made for radioiodine produced by decay of radiotellurium 
and for noble gases appearing in certain decay chains.  Iodine as a daughter of tellurium is 
assumed to be translocated instantaneously to the transfer compartment in inorganic form and 
then to follow the same kinetics as iodine introduced into blood as a parent radionuclide.  The 
assumption for noble gases varies with the radiological half-time and the site of production in the 
body.  For example, it is assumed that:  222Rn (T1/2 = 3.8 d) produced from 226Ra in soft tissues 
escapes from the body before decay; 70% of 222Rn produced in bone escapes from the body and 
the remaining 30% decays at the site of production; 220Rn (T1/2 = 56 s) produced from 224Ra 
decays at the site of production, either in soft tissues or bone; 20% of 83mKr (T1/2 = 1.83 h) 
produced from 83Rb decays at the site of production and the remaining 80% escapes from the 
body; and 79Kr (T1/2 = 35 h) produced from 79Rb escapes from the body. 
Experimental data on laboratory animals and postmortem data on human subjects 
indicate that many decay chain members produced in vivo behave much differently from the 
parent radionuclide (ICRP, 1993; ICRP, 1995a).  It appears that radionuclides born in soft tissues 
and, to some extent, on bone surfaces may relocate as if injected directly into blood, while 
radionuclides born in bone volume are more limited in their ability to migrate from the parent 
radionuclide.  With regard to inhaled material deposited in the lung, a reasonable default 
assumption may be that a radionuclide born in the respiratory tract remains with the parent if 
originating in an undissolved particle but otherwise translocates according to its own 
characteristic parameter values (i.e., values derived for that element assuming its direct 
deposition into the respiratory tract).  There is little information on the behavior of decay chain 
members produced in the gastrointestinal tract, but the rate of translocation through different 
segments of the tract should be relatively independent of the radionuclide.  In view of the tightly 
controlled and highly selective nature of absorption of material through the gastrointestinal tract 
wall, it seems reasonable to assume that the absorption fraction for decay chain members 
produced in the gastrointestinal tract contents is independent of absorption properties of the 
parent radionuclide. 
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For most decay chains, the assumption of shared kinetics was carried over to ICRP 
Publication 68 and to the ICRP’s series on intakes of radionuclides by members of the public.  
The assumption of independent kinetics of radioactive progeny is applied in those document in 
selected situations, as summarized in the following: 
1.  Iodine produced from decay of tellurium is assumed to be translocated at a fractional 
rate of 1000 d-1 to the transfer compartment in inorganic form and then to follow the 
same kinetics as iodine introduced into the transfer compartment as a parent radionuclide. 
2.  If the parent is an isotope of lead, radium, thorium, or uranium, then a radionuclide 
other than a noble gas formed in soft tissues or on bone surfaces is assigned the 
characteristic biokinetics of that radionuclide.  That is, it is assumed to have the same 
biokinetics as if the radionuclide had been taken in as a parent radionuclide.  A 
radionuclide other than a noble gas formed in bone volume is assigned the biokinetics of 
the parent.  Noble gases produced in soft tissues and bone surfaces are assumed to 
migrate from the body with a transfer coefficient of 100 d-1.  Noble gases produced in 
exchangeable and non-exchangeable bone volume are assumed to migrate from the body 
at rates of 1.5 d-1 and 0.36 d-1, respectively. 
 
The effects of these assumptions on dose coefficients are illustrated in Table 5.8 for 
selected radionuclides. 
In ICRP Publication 68 and ICRP documents on intakes of radionuclides by members of 
the public, radionuclides produced in the respiratory tract are assumed to have the same kinetics 
as the parent radionuclide while in the respiratory tract.  The rate of dissolution of the carrier of 
the radionuclide is assumed to control the rate of migration of inhaled radionuclides and their 
radioactive progeny.  An exception is made for 222Rn, which is assumed to escape from the body 
at a fractional rate of 100 d-1 after its production in any segment of the respiratory tract. 
Chain members produced in, or migrating to, the gastrointestinal tract after intake of the 
parent radionuclide are assigned the gastrointestinal absorption fraction (f1) of the parent in most 
cases.  For consistency with the treatment of the systemic biokinetics of radionuclides formed in 
vivo, exceptions are made if the parent is lead, radium, actinium, thorium, protactinium, or 
uranium.  In these cases, absorption of a chain member produced in vivo is assumed to be the 
same as if that chain member had been taken in as a parent radionuclide. 
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Table 5.8. Comparison of 50-y integrated doses following injection of 1 Bq of the 
parent into blood, based on alternate assumptions concerning biokinetics of decay chain 
members produced in vivo.  The ICRP’s updated biokinetic models were used in both 
cases. 
 
 
Ratio of dose coefficients A:B, where A is based 
on independent kinetics and B on shared kinetics 
 
 
 
 
Parent 
 
Effective dose 
 
Tissue most affected 
 
210Pb 
 
0.8 
 
11 (spleen) 
 
225Ra 
 
2.8 
 
9.7 (kidneys) 
 
226Ra 
 
1.0 
 
1.5 (kidneys) 
 
228Ra 
 
2.4 
 
12 (liver) 
 
227Th 
 
0.3 
 
0.3 (several organs) 
 
228Th 
 
0.5 
 
0.4 (several organs) 
 
232Th 
 
0.2 
 
0.2 (several organs) 
 
232U 
 
1.3 
 
1.8 (bone surface, red marrow) 
 
 
5.6.2. Detailed example:  Treatment of 232Th chain members produced in systemic tissues 
There is experimental evidence to support the assumption of independent kinetics for some 
chains of radionuclides, including some thorium chains (Leggett et al., 1984).  For example, 
activity ratios 224Ra:228Th in tissues and excreta of beagles injected with 228Th are consistent 
with the assumption that 224Ra born on bone surfaces migrates from 228Th over a period of days 
and then behaves as if injected directly into blood.  Time-dependent activity ratios of subsequent 
members of the 228Th chain also suggest redistribution consistent with the characteristic 
biokinetic models of individual members, although the extent of migration of these chain 
members and hence the interpretation of the data are limited by the short half-lives of the chain 
members. 
The assumption of independent kinetics was applied in ICRP Publication 69 (1995a) to 
chain members produced in vivo after absorption of thorium isotopes to blood, except that some 
simplifying assumptions were made in cases where there was little difference, in effect, between 
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the assumptions of shared and independent kinetics.  Parameter values for individual chain 
members can be found in Appendix C of ICRP Publication 71 (ICRP, 1995b).  The following 
general assumptions are made for members of thorium chains: 
 
1.  Radium isotopes formed in vivo are assumed to follow the model for radium as a 
parent (ICRP, 1993).  This requires that the model structure for thorium be expanded to 
include compartments that are in the radium model but not in the thorium model.   For 
example, each bone volume compartment in the thorium model must be divided into 
exchangeable and nonexchangeable bone volume compartments to describe the behavior 
of radium after its movement from plasma to bone surfaces to bone volume.  According 
to the radium model, bone contains about 30%, soft tissues about 15%, and excreta plus 
excretion pathways (mainly intestinal contents) about 55% of the injected amount at 1 d 
after injection of long-lived radium into blood of an adult.  Most radium atoms entering 
bone or soft tissues return to plasma within a few days.  By 100 d after injection, bone 
retains less than 5% and soft tissues less than 1% of the injected amount, the rest having 
been lost in excreta. 
 
2.  Radon produced in soft tissues or bone surfaces is assumed to move to plasma at a rate 
of 100 d-1.  Radon produced in the exchangeable and nonexchangeable bone volume 
compartments is assumed to migrate to plasma at rates of 1.5 and 0.36 d-1, respectively.  
Radon entering plasma is assumed to leave the body by exhalation at a rate of 1 min-1. 
3.  Lead isotopes formed in vivo are assumed to follow the model for lead as a parent 
(ICRP, 1993). Therefore, the model structure used to address a thorium chain that 
includes lead as a daughter must include compartments such as red blood cells and 
exchangeable and nonexchangeable bone volume that are in the lead model but are not 
identified separately in the thorium model.  According to the lead model, the approximate 
contents of various regions at 1 d after injection of long-lived lead into blood of an adult 
are as follows:  red blood cells, 59% (of the injected amount); bone, 15%; liver, 11%; 
kidneys, 5%; other soft tissues, 3%; and excreta plus excretion pathways, 7%.  Over the 
next few weeks there is a gradual shift of lead from red blood cells to bone, soft tissues, 
and excreta.  After 100 d, the predicted contents of the regions are as follows:  red blood 
cells, 4% (of the injected amount); bone, 22%; liver, 5%; kidneys, 2%; other soft tissues, 
5%; and excreta, 62%. 
 
4.  The model for polonium as a decay chain member is based on the non-recycling 
model for polonium as a parent given in ICRP Publication 67 (1993), but the latter model 
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is converted into a recycling model to fit into the framework used for thorium, radium, 
and lead.  Removal of polonium from all tissues except bone volume is assumed to occur 
at a rate of 0.1 d-1, with activity going to plasma.  Removal from bone volume to plasma 
is assumed to occur at the rate of bone turnover.  Of polonium reaching plasma, 10% 
goes to the upper large intestine, 5% to the urinary bladder contents, 30% to liver, 10% to 
kidneys, 5% to spleen, 10% to red marrow, and 45% to other tissues. 
 
5.  Bismuth is assumed to leave all tissues except bone volume at a rate of 0.035 d-1, with 
activity going to plasma.  From plasma, 35% goes to urine, 7% to feces via the intestines, 
35% to the kidneys, 5% to the liver, and 18% to other tissues. 
 
6.  Isotopes of thallium appearing in important thorium chains are short-lived and are 
assumed to decay at their point of origin.  Isotopes of actinium, protactinium, and 
thorium produced in vivo are assigned the model for thorium. 
 
The treatment of decay chain members is a particularly important consideration in the 
internal dosimetry of 232Th because the radioactive progeny of 232Th yield substantially more 
alpha energy than the parent over a period of years.  The estimated alpha activity of the total 
chain is reduced substantially if it is assumed, as indicated by available experimental data, that 
228Ra and subsequent chain members migrate over a period of hours or days from sites of 
production on bone surfaces and in soft tissues and then behave as if injected directly into blood 
(Tables 5.9 and 5.10). 
 
5.7.  Implications of biokinetic model updates for interpretation of bioassay data  
The ICRP’s updated models often lead to considerably different interpretation of 
bioassay data than would be made from the biokinetic models of ICRP Publication 30 or the 
related bioassay models of ICRP Publication 54 (1988b).  Potential differences are illustrated in 
Table 5.11, which gives estimated 50-year integrated absorbed doses for acutely inhaled 238U 
derived from measurements of urinary 238U made 24-48 h after intake.  It is assumed that 238U is 
inhaled in relatively insoluble form and the particle size is 5 µm (AMAD).  The large differences 
in dose estimates result from a combination of differences in predictions of the updated and 
previous respiratory models, systemic models, and f1 values. 
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Table 5.9.  Comparison of estimated 50-y integrated activities of 232Th and its decay chain 
members, assuming (A) independent or (B) shared kinetics ofdecay chain members, for the 
case of injection of 232Th into blood of an adult.a 
 
 
Ratio of integrated activities, A:B 
 
 
Radionuclide  
Cortical 
bone 
surface 
 
Trabecu-
lar bone 
surface 
 
Cortical 
bone 
volume 
 
Trabecu-
lar bone 
volume 
 
Red 
bone 
marrow 
 
 
 
Liver 
 
 
Testes, 
ovaries 
 
232Th 
 
1.0 
 
1.0 
 
1.0 
 
1.0 
 
1.0 
 
1.0 
 
1.0 
 
228Ra, 228Ac 
 
0.001 
 
0.003 
 
0.9 
 
0.7 
 
0.08 
 
0.04 
 
0.05 
 
228Th 
 
0.02 
 
0.06 
 
0.8 
 
0.5 
 
0.2 
 
0.06 
 
0.05 
 
224Ra through 208Tl 
 
~0.005 
 
~0.02 
 
~0.8 
 
~0.5 
 
~0.1 
 
~0.05 
 
~0.05 
aThe biokinetic model for thorium given in ICRP Publication 69 (ICRP, 1995a) is applied to 232Th.  For 
the case of independent kinetics, the models and assumptions of Publication 69 are applied to the 
radioactive progeny of 232Th. 
 
Table 5.10.  Comparison of ICRP’s updated (ICRP, 1995a) and previous (ICRP, 1979) 
models as predictors of 50-y integrated activity after acute intake of 232Th by an adult. 
 
 
Ratio of integrated activities 
(updated models : previous models)  
 
Injection 
 
Ingestion 
 
Inhalation 
 
 
 
 
 
Compartment 
 
232Th 
 
228Raa 
 
232Th 
 
228Raa 
 
232Th 
 
228Raa 
 
Trabecular surfaces 
 
0.49 
 
0.0014 
 
1.2 
 
0.0036 
 
0.39 
 
0.0011 
 
Cortical surfaces 
 
2.3 
 
0.0026 
 
5.7 
 
0.0064 
 
1.8 
 
0.0020 
 
Liver 
 
11 
 
1.4 
 
27 
 
3.5 
 
8.4 
 
1.0 
 
Kidneys 
 
110 
 
9.0 
 
280 
 
23 
 
86 
 
7.0 
 
Gonads 
 
60 
 
8.9 
 
150 
 
22 
 
47 
 
7.0 
 
Other 
 
25 
 
56 
 
62 
 
140 
 
19 
 
42 
aRefers to 228Ra produced in the body after intake of 232Th. 
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The implications of the revised models with regard to interpretation of bioassay data are 
more difficult to generalize or summarize than those for dose coefficients, because differences in 
back calculations from bioassay data depend not only on the radionuclide and exposure mode but 
also on the time after intake.  Consider, for example, the case of inhalation of a relatively 
insoluble form of thorium (Type S or Class Y) in 1-µm (AMAD) particles.  Urinary excretion 
rates predicted by the previous respiratory tract model and systemic model for thorium (ICRP 
1979, 1988b) and the current models (ICRP 1995a, 1997) are shown in Figure 5.8.  The ratio of 
predicted excretion rates (updated models : previous models) ranges from about 2 to about 20, 
depending on the observation time.  Large differences in predictions of intake based on previous 
and updated methods may not lead to large differences in dose estimates, provided the dose 
coefficients are based on the same models as the backward calculations of intake.  This is 
because the same models that yield relatively high estimates of intake from bioassay data often  
 
 
Table 5.11.  Comparison of dose estimates based on updated and previous ICRP models 
and recommendations for the case of acutely inhaled 238U (insoluble, 5 µm AMAD), back-
calculating from urinary excretion measured 24-48 h after intake. 
 
 
 
Tissue 
 
Ratio of absorbed dose estimates  
ICRP Pub. 68 : ICRP Pub. 30 
 
Bone surface 
 
9.7 
 
Breast 
 
110 
 
Colon 
 
17 
 
Kidneys 
 
8.6 
 
Lung 
 
7.5 
 
Red marrow 
 
15 
 
Testes 
 
130 
 
Effective (E:HE) 
 
11 
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Figure 5.8.  Urinary excretion rates for inhaled thorium predicted 
by the previous respiratory tract model and systemic model for 
thorium (ICRP 1979, 1988b) and the current models (ICRP 1995a, 
1997).  Thorium is assumed to be inhaled in insoluble form (Type S 
or Class Y).  The assumed particle size is 1-µm (AMAD).   
 
 
yield relatively low estimates of dose per unit intake.  For example, the updated models yield a 
2- to 20-fold higher estimate of inhalation intake of insoluble 232Th based on one or more 
measurements of urinary 232Th (Figure 5.8).  In an estimate of the resulting effective dose, 
however, the higher estimate of intake may be largely offset by the fact that the updated effective 
dose coefficient for inhaled 232Th in insoluble form is about 14-fold lower than the effective dose 
coefficient from ICRP Publication 30.  If intake of 232Th is estimated from a urinary 
measurement made at a time when the curves in Figure 5.8 differ by a factor of 20, then there is 
only a modest difference in the alternate estimates of effective dose.  If the measurement of 
urinary 232Th is made at a time when the two curves differ by a factor of 2, then the two 
estimates differ considerably. 
In practice, calculations of intake of a radionuclide often are based on measurements of 
decay chain members rather than the parent radionuclide.  For example, intake of 232Th may be 
estimated from external measurement of total-body 212Pb or 208Tl.  Due to the considerable 
changes in recent years in the ICRP’s assumptions concerning the fate of some decay chain 
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members produced in the body, the previous and updated models can yield considerably 
different estimates of intake based on measurement of decay chain members. 
 
 5.8. The ICRP’s age-specific systemic biokinetic models 
 
5.8.1. Elements for which age-specific models have been developed 
The ICRP’s series of documents on intakes of radionuclides by members of the public 
(ICRP, 1989, 1993, 1995a, 1995b, 1996) provides age-specific biokinetic models for 31 
elements:  hydrogen, carbon, sulfur, calcium, iron, cobalt, nickel, zinc, selenium, strontium, 
zirconium, niobium, molybdenum, technetium, ruthenium, silver, antimony, tellurium, iodine, 
cesium, barium, cerium, lead, polonium, radium, thorium, uranium, neptunium, plutonium, 
americium, and curium.  The 31 models represent a variety of modeling approaches. 
 
5.8.2.  Physiologically based models for bone-seeking radionuclides 
As described earlier, the ICRP has adopted a generic, physiologically based model 
structure for bone-volume-seeking radionuclides and a similar but separate generic structure for 
bone-surface-seeking radionuclides. These models have been applied to workers but were 
developed for consideration of environmental intakes of radionuclides by adults or children and 
have age-specific parameter values.  Some of the parameter values describing translocation of 
skeletal activity are generic and are based on basic physiological information on bone 
restructuring.  Other parameter values are element-specific and are selected from available data 
on the element of interest and its physiological analogues in human subjects and laboratory 
animals. The quantity and quality of available age-specific information varies considerably form 
one bone-seeking element to another.  For example, there is a sizable database on the age-
specific biokinetics of calcium or strontium, smaller but useful databases for radium or lead, and 
relatively little direct information on the age-specific biokinetics of barium or uranium.  The age-
specific biokinetics of plutonium has been studied frequently in laboratory animals, but there is 
not much age-specific information on most other bone-surface-seeking radionuclides. 
Consider, for example, the age-specific biokinetic database on strontium.  A large data 
base related to the transfer of 90Sr from food and milk to the human skeleton was developed in 
the 1950s and 1960s, although interpretation of this information is complicated by the fact that 
measured skeletal burdens were accumulated over an extended period.  More easily interpreted 
but more limited age-specific data on the systemic biokinetics of strontium in human subjects are 
available from controlled studies.  Because strontium is a close physiological analogue of 
calcium, data from controlled studies of calcium in humans provide supporting information for 
selection of age-specific parameter values for strontium.  The use of a physiologically 
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descriptive model framework allows age-specific data on human subjects and laboratory animals 
to be superimposed on information concerning addition and turnover of skeletal calcium and 
restructuring of bone.  Experimental and environmental data on strontium in humans subjects 
were used as primary sources of information but were supplemented with data on the behavior of 
strontium and its physiological analogues in laboratory animals, and data on the behavior of 
physiological analogues of strontium in humans.  For example, data on laboratory animals 
provide evidence that the initial uptake by bone is similar for all alkaline earth elements.  This 
strengthens confidence in estimates of the biokinetics of strontium at early times after intake, for 
which there are reasonably good data on human subjects but little information regarding the 
division between bone and soft tissues in those subjects.  Age-specific data on strontium in dogs 
help strengthen confidence in judgments, based mainly on fallout data, concerning relative 
patterns of buildup and decline of strontium in bone at different stages of bone development. 
Thorium provides an example of a bone-seeking radionuclide for which there is relatively 
little direct information on age-specific biokinetics.  The model was developed within the 
generic structure for bone-surface-seeking radionuclides (Figure 5.6).  Default assumptions 
concerning the relative kinetics of bone seekers in children and adults were used in ICRP 
Publication 69 (1995a) to extend parameter values from adults to children.  These assumptions 
are based on numerous observations of the age-specific biokinetics of various bone seekers in 
laboratory animals and, to a lesser extent, human subjects.  It is postulated that differences with 
age in the biokinetics of a bone-seeking radionuclide is determined largely by three factors:  
increased fractional transfer from plasma to bone in children in association with elevated bone 
formation rates in the maturing skeleton; decreased fractional transfer from plasma to soft tissues 
and excreta in children due to relatively greater competition from immature bone; and an 
elevated rate of transfer from bone to plasma in children due to an elevated rate of bone turnover. 
 For actinide elements, the additional assumption is made that fractional deposition in the gonads 
at a given age depends on the mass of the gonads at that age.  Except where there is evidence to 
the contrary, removal half-times from soft tissues, bone surfaces, and exchangeable bone volume 
are assumed to be independent of age.  Age-specific parameter values of the ICRP’s systemic 
biokinetic model for thorium are given in Table 5.12. 
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Table 5.12.  Age-specific transfer coefficients (d-1) in the systemic 
biokinetic model for thorium (ICRP, 1995a). 
 
 
 
 
Age (y) 
 
                        
Pathwaya 
 
Infant 
(100 d) 
 
 
1 y 
 
 
5 y 
 
 
10 y 
 
 
15 y 
 
 
Adult 
 
Blood to Liver 1           
Blood to Cort Surf 
Blood to Trab Surf 
Blood to UBC 
Blood to Urinary Path 
Blood to OKT 
Blood to LI Contents 
Blood to Testes 
Blood to Ovaries 
Blood to ST0 
Blood to ST1 
Blood to ST2 
ST0 to Blood 
Urinary Path to UBC 
OKT to Blood 
ST1 to Blood 
ST2 to Blood 
Trab Surf to Trab Vol 
Trab Surf to Bone Marrow 
Cort Surf to Cort Vol 
Cort Surf to Bone Marrow 
Trab Vol to Bone Marrow 
Cort Vol to Bone Marrow 
Bone Marrow to Blood 
Liver 1 to Liver 2 
Liver 1 to SI Contents 
Liver 1 to Blood 
Liver 2 to Blood 
Testes/Ovaries to Blood 
 
0.0647 
0.7763   
0.7763 
0.0711 
0.0453 
0.0129 
0.00647 
0.000039 
0.000023 
0.832 
0.162 
0.0259 
0.462 
0.0462 
0.00038 
0.00095 
0.000019 
0.00822 
0.00822 
0.00822 
0.00822 
0.00822 
0.00822 
0.0076 
0.00095 
0.000475  
0.000475 
0.000211   
0.00019   
 
0.0647 
0.7763 
0.7763 
0.0711 
0.0453 
0.0129 
0.00647 
0.000058 
0.000030 
0.832 
0.162 
0.0259 
0.462 
0.0462 
0.00038 
0.00095 
0.000019 
0.00288 
0.00288 
0.00288 
0.00288 
0.00288 
0.00288 
0.0076 
0.00095   
0.000475    
0.000475  
0.000211 
0.00019     
 
0.0647 
0.7763 
0.7763 
0.0711 
0.0453 
0.0129      
0.00647   
0.000066 
0.000076 
0.832 
0.162 
0.0259 
0.462 
0.0462 
0.00038     
0.00095 
0.000019 
0.00181 
0.00181 
0.00153   
0.00153 
0.00181 
0.00153 
0.0076 
0.00095 
0.000475 
0.000475  
0.000211   
0.00019 
 
0.0647 
0.7763    
0.7763 
0.0711 
0.0453 
0.0129 
0.00647 
0.000077 
0.00013 
0.832 
0.162 
0.0259 
0.462 
0.0462 
0.00038 
0.00095 
0.000019 
0.00132 
0.00132 
0.000904 
0.000904 
0.00132 
0.000904 
0.0076 
0.00095   
0.000475 
0.000475  
0.000211 
0.00019 
 
0.0647 
0.7763   
0.7763   
0.0711 
0.0453   
0.0129 
0.00647 
0.00062 
0.00023 
0.832 
0.162 
0.0259  
0.462 
0.0462 
0.00038 
0.00095 
0.000019 
0.000959 
0.000959 
0.000521 
0.000521 
0.000959 
0.000521 
0.0076 
0.00095   
0.000475  
0.000475  
0.000211  
0.00019 
 
0.0970 
0.6793 
0.6793 
0.1067 
0.0679 
0.0194 
0.00970 
0.00068 
0.00021 
0.832 
0.243 
0.0388 
0.462 
0.0462 
0.00038 
0.00095 
0.000019 
0.000247 
0.000493 
0.0000411 
0.0000821 
0.000493 
0.0000821 
0.0076 
0.00095 
0.000475 
0.000475 
0.000211 
0.00019 
 
 
aCort = Cortical, Trab = Trabecular, Surf = Surface, Vol = Volume, UBC = Urinary Bladder Contents, 
OKT = Other Kidney Tissue, LI = Large Intestine, SI = Small Intestine. 
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5.8.3.  Age-specific models for frequently studied elements other than bone seekers 
The age-specific biokinetics of a few other elements (i.e., other than bone seekers) can be 
characterized on the basis of experimental or environmental data and/or information on the 
processes controlling their behavior in the human body.  The best understood elements in this 
regard are hydrogen (tritium, as tritiated water or HTO), cesium, iodine, carbon, and iron. 
In the ICRP's biokinetic model for 3H as HTO, activity is assumed to be uniformly 
distributed in the body.  Whole-body retention at t days after injection is described by a sum of 
two exponential terms: 
R(t) = 0.97exp(-0.693t/T1) + 0.03exp(-0.693t/T2). 
The coefficients are assumed to be independent of age, but the half-times T1 and T2 are assumed 
to decrease with decreasing age, based on an assumed equivalence of tritium turnover and body 
water turnover.  For the adult, T1 = 10 d, and T2 = 40 d.  The theoretical model predicts that the 
short-term half-time of tritium, representing 97% of the amount of tritiated water consumed, is 
3.0, 3.5, 4.6, 5.7, 7.9, and 10 d at ages 3 mo, 1 y, 5 y, 10 y, 15 y, and adulthood, respectively.  
The long-term half-times at these ages are assumed to be 8, 15, 19, 26, 32, and 40 d, 
respectively.  Data for workers exposed to tritiated water are consistent with the theoretical 
model. 
The age-specific model for cesium is similar in form to the tritium model.  Cesium is 
assumed to be uniformly distributed in the body.  Whole-body retention t days after injection is 
described by a sum of two exponential terms: 
R(t) = a exp(-0.693t/T1) + (1 - a) exp(-0.693t/T2). 
The values a, T1, and T2 vary with age, based on observations of more rapid turnover of cesium 
in children than in adults and established relations between the parameter values and total-body 
potassium.  For the adult, a = 0.1, T1 = 2 d, and T2 = 110 d.  For ages 100 d and 1 y, the model 
has only one term, with half-times of 16 d and 13 d, respectively.  For ages 5, 10, and 15 y, the 
coefficient a is 0.45, 0.30, and 0.13, respectively; the short-term half-time T1 is 9.1, 5.8, and 2.2 
d, respectively; and the long-term half-time T2 is 30, 50, and 93 d, respectively. 
 The structure of the ICRP’s recycling model for iodine is shown in Figure 5.1.  Age-
specific parameter values were based largely on observed differences with age in the behavior of 
iodine in human subjects, but selection of central values for a given age was complicated by 
considerable variability in the biokinetics of iodine.  According to the model for the adult, 30% 
of iodine entering blood is taken up by the thyroid gland and the remainder is excreted in urine. 
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Iodine leaves the thyroid in organic form with a biological half-time of 80 d and is metabolized 
by the tissues in the rest of the body.  Iodine is removed from tissues other than the thyroid with 
a biological half-time of 12 d.  It is assumed that 20% of iodine leaving these other tissues is 
excreted in feces.  The remainder is assumed to return to blood in inorganic form and to behave 
the same as the original input to blood.  Turnover of iodine in the thyroid and other tissues is 
assumed to be faster in children than in adults.  Specifically, biological half-times in the thyroid 
at ages 3 mo and 1, 5, 10, and 15 y are assumed to be about 11, 15, 23, 58, and 67 d, 
respectively.  For each age, the biological half-time in other tissues is assumed to be 10% of that 
in thyroid. 
A model of the age-specific biokinetics of carbon was built from observations on 
laboratory animals together with balance considerations for carbon.  Carbon is assumed to be 
uniformly distributed in the body, and removal is assumed to be described by a single half-time.  
The assigned half-time at ages 100 d, 1 y, 5 y, 10 y, 15 y, and adult is 8, 15, 19, 26, 32, and 40 d. 
 A detailed, physiologically realistic model structure was developed for iron.  Age-
specific parameter values, which will not be given here, are based on estimates of the sizes of the 
body’s main iron pools (hemoglobin, myoglobin, liver, and red marrow) as a function of age, 
together with methods proposed in the literature for scaling iron kinetics. 
 
5.8.4.  Age-specific models for remaining elements 
Age-specific models for the remaining elements were developed on the basis of best 
available, but generally weak, evidence for each element.  The biokinetics of polonium is 
assumed to be invariant with age on the basis of limited data for children suggesting whole-body 
retention times not greatly different from those determined in adults.  For zirconium and zinc, 
parameter values for the adult are assigned to infants and children, except that activity is 
assumed to be removed from bone at the rate of bone turnover.  For niobium and cerium, it is 
assumed that fractional uptake by the skeleton is elevated and uptake by soft tissues is decreased 
at younger ages but that removal half-times are invariant with age.  For sulfur, cobalt, nickel, 
selenium, molybdenum, technetium, ruthenium, silver, antimony, and tellurium, the model for 
the adult is assigned to all age groups in the absence of pertinent age-specific data. 
 
 5.9. Differences in predictions of systemic biokinetic models for workers and the public 
 
For some radionuclides, dose coefficients given in the ICRP’s series on environmental 
exposures vary substantially with age as a net result of the application of age-specific tissue 
masses and biokinetic parameter values. For selected radionuclides, an analysis was performed 
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to determine whether the age-specific parameter values alone are of much consequence with 
regard to dose estimates, i.e., whether they yield substantially different estimates of cumulative 
activity in tissues for different ages at intake.  To avoid the complications of differences with age 
in fractional absorption of inhaled or ingested radionuclides, intake was assumed to be by 
intravenous injection.  Results of the analysis are summarized in Table 5.13.  Evidently, the 
cumulative activity is invariant with injection age for isotopes of elements for which the ICRP 
applied parameter values for the adult to all age groups (e.g., cobalt, ruthenium, antimony, and 
polonium).  In such cases, dose coefficients may vary substantially with age due solely to 
differences in tissue masses.  For uniformly distributed radionuclides whose total-body retention 
time is assumed to decrease with age (e.g., 3H, 14C, and 137Cs), cumulative activity in the total 
body increases substantially between infancy and adulthood and tends to offset the increase in 
body mass in the derivation of dose coefficients.  For the relatively short-lived radionuclide 131I, 
the substantial increase with age in the assumed half-time in the thyroid does not result in a 
corresponding difference with age in predicted cumulative activity in the thyroid because the 
model predicts that most of the atoms deposited in the thyroid will decay there before they can 
be removed by biological removal.  This results in considerable difference with age in the 
estimated dose to thyroid and the effective dose from ingested 131I, for example, due to the 
considerable changes with age in the mass of the thyroid 
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Table 5.13.  For selected radionuclides and tissues, cumulative activity 
for different ages at injection, relative to the adult. 
 
Cumulative activity in tissue divided by 
corresponding value for the adult 
 
 
Radionuclide 
 
 
 
Tissue  
Injection age 100 d 
 
Injection age 10 y 
 
H-3 
 
Total body 
 
0.3 
 
0.6 
 
C-14 
 
Total body 
 
0.2 
 
0.7 
 
Fe-55 
 
Red marrow 
Liver 
 
0.5 
0.7 
 
1.1 
0.8 
 
Co-60 
 
All tissues 
 
1.0 
 
1.0 
 
Sr-90 
 
Trabecular bone volume 
Cortical bone volume 
 
0.4 
0.7 
 
0.9 
2.0 
 
Ru-106 
 
All tissues 
 
1.0 
 
1.0 
 
Sb-126 
 
All tissues 
 
1.0 
 
1.0 
 
I-131 
 
Thyroid 
 
0.7 
 
1.0 
 
Cs-137 
 
Total body 
 
0.2 
 
0.4 
 
Pb-210 
 
Trabecular bone volume 
Cortical bone volume 
 
0.2 
0.4 
 
0.5 
1.1 
 
Po-210 
 
All tissues 
 
1.0 
 
1.0 
 
Ra-226 
 
Trabecular bone volume 
Cortical bone volume 
 
0.2 
0.7 
 
0.9 
1.9 
 
Th-232 
 
Trabecular bone surface 
Cortical bone surface 
Liver 
 
0.7 
0.4 
1.5 
 
0.9 
0.7 
1.1 
 
U-238 
 
Trabecular bone volume 
Cortical bone volume 
Kidney 
 
0.3 
0.4 
1.0 
 
0.7 
1.4 
1.0 
 
Pu-239 
 
Trabecular bone surface 
Cortical bone surface 
Liver 
 
0.5 
0.4 
0.9 
 
0.7 
0.6 
0.9 
 
Cm-240 
 
Trabecular bone surface 
Cortical bone surface 
Liver 
 
1.5 
1.9 
0.2 
 
1.5 
1.6 
0.6 
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 6.  CONCLUSIONS:  NET EFFECTS OF UPDATED ICRP 
 MODELS AND RECOMMENDATIONS ON DOSE ESTIMATES 
 
This section summarizes major changes in the ICRP’s dosimetric scheme since the 
appearance of ICRP Publication 30 and describes the net effects of those changes on dose 
coefficients for inhalation or ingestion of radionuclides. 
 
 6.1. Summary of main changes in the ICRP’s dosimetric scheme  
 
6.1.1. Tissue weighting factors 
The tissue weighting factors used in ICRP Publication 30 are those recommended in 
ICRP Publication 26 (1977).  The latter publication was superseded by Publication 60 (1991), 
which provides a modified and expanded set of tissue weighting factors.  In the majority of 
cases, effective dose coefficients for inhalation and ingestion are relatively insensitive to the 
changes in the tissue weighting factors.  In some cases, however, effective dose coefficients are 
noticeably affected by some combination of the following modifications of the tissue weighting 
factors: a threefold reduction of the weighting factor for bone surface; a 67% increase in the 
weighting factor for thyroid; introduction of explicit weighting factors for colon and stomach; a 
sixfold decrease in the weight of Remainder, which affects the contribution of tissues such as the 
kidneys that are not named explicitly in either set of weighting factors; and introduction of the 
splitting rule.  The splitting rule states that a tissue in Remainder is given half the weight of 
Remainder if it receives a dose in excess of that received by any of the 12 tissues for which 
weighting factors are specified.  The splitting rule has a particularly large influence on the 
effective dose for inhalation of many short-lived radionuclides due to the high dose to the 
extrathoracic region of the respiratory tract, which has no explicit weighting factor. 
 
6.1.2. Respiratory tract model 
The ICRP’s updated respiratory tract model, introduced in ICRP Publication 66 (1994b), 
differs considerably from the Task Group Lung Model (TGLM) used in ICRP Publication 30 
with regard both to structure and predictions.  In contrast to the TGLM, the updated model 
addresses differences with age, gender, breathing rate and other factors in total and regional 
deposition of inhaled material in the respiratory tract.  For the reference adult male, the updated 
model predicts lower total deposition in the respiratory tract and lower deposition in the lower 
lungs than does the TGLM for most particle sizes.  Compared with the TGLM, the updated 
model predicts much different rates of absorption from the respirator tract to blood.  Estimates of 
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lung dose derived with the TGLM are based on the assumption, in effect, that the total activity in 
the lungs is uniformly distributed in the total blood-filled lungs weighing 1000 g.  Estimates 
based on the updated respiratory model address the heterogeneous distribution of radiosensitive 
cells within the respiratory tract.  Differences in the biokinetic and dosimetric properties of the 
two respiratory models lead to substantially different estimates of lung dose in many cases. 
 
6.1.3.  Gastrointestinal absorption fractions 
Since the appearance of ICRP Publication 30 the ICRP has updated its gastrointestinal 
absorption fractions (f1 values) for a number of elements.  Revisions were largely in connection 
with the development of age-specific values for application to members of the public, but some 
of the updated values assigned to adult members of the public have also been applied to workers. 
For the worker, substantial changes have been made in f1 values for at least some forms of 
cobalt, tellurium, lanthanide elements, and actinide elements including uranium. The largest 
absolute changes are a decrease from 0.3 to 0.1 for forms of cobalt other than oxides and 
hydroxides and a decrease from 0.05 to 0.02 for soluble forms of uranium. 
For some elements, the f1 values recommended for evaluation of environmental intakes 
differ considerably from the values recommended in ICRP Publication 30.  For example, a value 
of 0.5 is recommended for environmental intake of polonium by an adult, compared with the 
value of 0.1 used in ICRP Publication 30 for occupational intake of polonium.  The ICRP’s f1 
values for infants are up to an order of magnitude greater than those for adult members of the 
public for some poorly absorbed elements such as plutonium and thorium. 
The effect of the changes in the f1 values on dose coefficients depends strongly on the 
radionuclide and tissue, varying from virtually no effect to a change in proportion to the 
modification of f1.  When the f1 value is changed from one relatively small number to another, 
the dose to the colon may be affected very little because the nearly unchanged cumulative 
activity may be the main determinant of the dose to the colon.  If the effective dose is determined 
largely by the dose to the colon, then the effective dose may be changed little by a substantial 
change in f1 due to the small change in the colon dose.  Doses to systemic tissues change nearly 
in proportion to f1 in most cases, but this is not the case when doses to systemic tissues arise 
mainly from penetrating radiations originating in the intestinal contents. 
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6.1.4. Systemic biokinetic models 
The ICRP’s documents on environmental intakes of radionuclides provide age-specific 
systemic biokinetic models for 31 elements.  The models for some elements are more detailed 
and physiologically realistic than the corresponding models in ICRP Publication 30.  For other 
elements, the age-specific models are similar in format to the simplistic retention functions used 
in ICRP Publication 30.  The systemic models developed for adult members of the public were 
generally applied to workers in ICRP Publication 68 (1994a). 
In ICRP Publication 30, decay chain members produced in the body generally were 
assigned the biokinetic model of the parent radionuclide; this is referred to as “shared kinetics” 
of decay chains.  The assumption of shared kinetics is still used by the ICRP for many decay 
chains, but an apparently more realistic assumption of “independent kinetics” is now applied to 
some chains.  If the parent is an isotope of lead, radium, thorium, or uranium, then a radionuclide 
(other than a noble gas) formed either in soft tissues or on bone surfaces is assumed to have the 
same biokinetics as if the radionuclide had been taken in as a parent radionuclide, and a 
radionuclide formed in bone volume is assigned the biokinetics of the parent.  Dose coefficients 
for some but not all parent radionuclides are relatively insensitive to assumptions concerning the 
fate of decay chain members. 
 
 6.2.  Extent of changes in ICRP’s dose coefficients for workers 
A comparison was made of dose coefficients for workers based on models of ICRP 
Publication 68 and Publication 30.  The analysis addressed both inhalation and ingestion of 
radionuclides in the work place and included all (~800) radionuclides addressed in ICRP 
Publication 30.  The tissues considered were the lungs, stomach wall, colon wall, bone surface, 
red marrow, liver, thyroid, breast, testes, and muscle.  The solubility classes considered for a 
given radionuclide were those considered in ICRP Publication 30.  Dose coefficients for the 
absorption types, Type F, Type M, and Type S, currently used by the ICRP were compared with 
coefficients for Class D, W, and Y compounds, respectively, as defined in ICRP Publication 30.  
Inhalation dose coefficients generated by models of ICRP Publication 30 were based on the 
default particle size of 1 µm (AMAD) recommended in that document, and coefficients 
generated by models of ICRP Publication 68 were based on the default particle size of 5 µm 
recommended in that document.  Comparisons were made in terms of the ratio of the dose 
coefficient from ICRP Publication 68 to that from ICRP Publication 30. 
 Results are summarized in Figure 6.1 in the form of separate histograms for inhalation 
and ingestion of radionuclides.  The histogram for a given mode of intake shows the percentages 
of ratios of dose coefficients (ICRP 68 : ICRP 30) that fall above or below specified values.  
Overall, differences in the two sets of dose coefficients are greater for inhalation than for 
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ingestion.  For inhalation, ~40% of the ratios fall in the range 0.7-1.5; ~4% of the ratios are 
greater than 10; and ~1.4% are less 0.1.  For ingestion, ~73% of the ratios fall in the range 0.7-
1.5; ~3.4% are greater than 10, and ~1.3% are less than 0.1.  Examples of cases in which the 
models of Publication 68 and Publication 30 yield substantially different dose coefficients for 
specific tissues are given in Table 6.1. 
 
 
 
Figure 6.1.  Overall effect of the ICRP’s updated models and 
recommendations on tissue dose coefficients.  The histogram for a given 
mode of intake shows the percentages of ratios of dose coefficients 
(ICRP 68 : ICRP 30) that fall above or below specified values.   
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Table 6.1.  Examples of substantial differences in corresponding tissue dose coefficients 
from ICRP Publication 68 and ICRP Publication 30. 
 
 
 
Radionuclide 
 
 
Type of exposure  
 
Tissue 
 
Ratio 
(ICRP 68 : 
ICRP 30) 
 
 
 
Tissue 
 
Ratio 
(ICRP 68 : 
ICRP 30) 
 
Be-10 
 
Inhalation  (S or Y) 
 
Bone surface 
 
0.16 
 
Lung 
 
0.19 
 
Zr-93 
 
Inhalation  (S or Y) 
 
Breast 
 
0.07 
 
Lung 
 
0.09 
 
Ba-131m 
 
Inhalation (F or D) 
 
Colon 
 
4.3 
 
Bone surface 
 
3.0 
 
Tc-101 
 
Inhalation (M or W) 
 
Stomach wall 
 
16 
 
Colon 
 
7.2 
 
Bi-214 
 
Inhalation (M or W) 
 
Stomach wall 
 
8.9 
 
Lung 
 
6.0 
 
Th-232 
 
Inhalation  (S or Y) 
 
Bone surface 
 
0.03 
 
Red marrow 
 
0.02 
 
U-238 
 
Inhalation  (S or Y) 
 
Lung 
 
0.13 
 
Liver 
 
11 
 
Np-237 
 
Inhalation (M or W) 
 
Breast 
 
52 
 
Thyroid 
 
0.09 
 
Pu-239 
 
Inhalation  (S or Y) 
 
Red marrow 
 
0.07 
 
Breast 
 
390 
 
C-11 
 
Ingestion 
 
Stomach wall 
 
55 
 
Thyroid 
 
0.34 
 
Mo-93 
 
Ingestion 
 
Bone surface 
 
45 
 
Red marrow 
 
53 
 
Te-123 
 
Ingestion 
 
Breast 
 
150 
 
Liver 
 
170 
 
Th-232 
 
Ingestion 
 
Breast 
 
28 
 
Liver 
 
18 
 
Am-241 
 
Ingestion 
 
Thyroid 
 
1200 
 
Lung 
 
460 
 
 
As a weighted sum of tissue doses, the effective dose generally is less sensitive than 
individual tissues to changes in biokinetic and dosimetric models.  Nevertheless, cases arise in 
which the ICRP’s current effective dose coefficient E for occupational intake of a radionuclide is 
substantially different from the coefficient HE given in ICRP Publication 30.  Several such cases 
are listed in Table 6.2, which addresses inhalation, and Table 6.3, which addresses ingestion.  In 
each table, the radionuclides are grouped into cases in which the effective dose coefficients have 
been changed to roughly the same extent for generally the same reasons.  For each group, the last 
column of the table indicates the main reasons for the change in the effective dose coefficients. 
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Table 6.2.  For occupational intake of radionuclides by inhalation, examples of effective 
dose coefficients E from ICRP Publication 68 that differ substantially from the 
corresponding coefficients HE of ICRP Publication 30. 
 
 
Radionuclides 
 
Type 
 
E:HE 
 
 
Changes in ICRP models contributing most heavily 
to change in effective dose coefficient 
 
Mo-93 
 
F 
 
~5 
 
Addition of long-term retention component for bone 
to systemic biokinetic model. 
 
Ba-131m 
 
F 
 
5 
 
Updated systemic biokinetic model with high 
secretion into colon; introduction of explicit 
weighting factor for colon; high dose to ET region of 
lungs; introduction of splitting rule for Remainder. 
 
Tc-101, Re-177, Re-178, 
Hg-199m 
 
M 
 
~5 
 
Explicit weighting factor for stomach; stomach 
tissue is a source organ for Tc and Re. 
 
Ag-104, In-112, In-116m, In-117, 
Sb-116m, Sb-128a, Ho-157, 
Ho-159, Ho-162, Ho-164, Tm-175, 
Lu-178m, Hf-177m, Hf-182m, Os-
180, Np-233 
 
M 
 
5-7 
 
Explicit weighting factors for stomach and/or colon. 
 
Bi-212, Bi-213, Bi-214, Th-226, 
Am-237, Am-246 
 
M 
 
8-13 
 
High dose to ET region of lungs; introduction of 
splitting rule for Remainder; high weight given to 
dose to bronchial tissues. 
 
Ac-227, Th-229, Np-232, 
Np-236a, Np-236b, Np-237, 
Np-238 
 
M 
 
0.10-0.12 
 
Reduced absorption to blood; reduced dose 
estimates for bone surface due to updated systemic 
biokinetic model, including treatment of decay chain 
members in some cases; reduced weighting factor 
for bone surface. 
 
Be-10, Mo-93, Pd-107, Pm-145, 
Lu-176, Ir-192m,  
 
S 
 
0.08-0.2 
 
Lower deposition in deep lung due to changes in 
deposition model and default particle size.  Dose to 
deep lung main contributor to effective dose. 
 
Zr-93; Ac-227, Th-229, Th-230, 
Th-232, U-233, U-234, U-235, 
U-236, U-238, Pu-238, Pu-239, 
Pu-240, Pu-241, Pu-242, Pu-244 
 
S 
 
0.06-0.2 
 
Reduced deposition in deep lungs; reduced 
absorption to blood; lower dose estimates for bone 
surface often given by updated systemic models 
and/or treatment of decay chain members; reduced 
weighting factor for bone surface.  
 
Hg-193, Hg-193m, Hg-195, 
Hg-195m, Hg-197, Hg-197m, 
Hg-199m 
 
V 
 
15-25 
 
Assignment of mercury vapor to bound 
compartments of respiratory tract, which are close 
to sensitive cells. 
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Table 6.3.  For occupational intake of radionuclides by ingestion, examples of effective dose 
coefficients E from ICRP Publication 68 that differ substantially from the corresponding 
coefficients HE of ICRP Publication 30. 
 
 
Radionuclides 
 
E:HE 
 
 
Changes in ICRP models contributing most heavily to 
change in effective dose coefficient 
 
C-11 
 
7 
 
Change from assumption of instantaneous distribution of 
ingested (or inhaled) C-11 among tissues to residence in 
stomach, together with introduction of explicit tissue 
weighting factor for stomach. 
 
Mo-93 
 
7 
 
Addition of long-term retention component for bone to 
systemic biokinetic model. 
 
Ge-68, Ge-71 
 
4-5 
 
Introduction of explicit weighting factor for colon, together 
with explicit transfer of excreted Ge through intestines (and 
urinary bladder) rather than directly to excreta as in ICRP 
Publication 30.  
 
Several actinides, including 
Np-236a, Np-237, Pu-236, Pu-238, 
Pu-239, Pu-240, Pu-241, Pu-242, 
Pu-244, Am-241, Am-242m, 
Am-243, Cm-243, Cm-244, 
Cm-245, Cm-246, Cm-247 
 
0.08-0.33 
 
Decrease in f1 values.  Substantially different systemic 
biokinetic models for bone surface seekers, depicting 
burial in bone volume and resulting in lower dose 
estimates for bone surface and red marrow.  Reduction of 
tissue weighting factor for bone surface. 
 
 
As is the case for the dose coefficients for individual tissues, substantial changes in 
effective dose coefficients are seen more frequently for inhalation than for ingestion.  This is due 
primarily to the substantial differences in the previous and updated respiratory tract models. 
 Some of the largest differences in the effective dose coefficients of ICRP Publication 68 
and those of ICRP Publication 30 are seen for inhaled mercury vapor.  For inhalation of 193Hg, 
193mHg, 195Hg, 195mHg, 197Hg, 197mHg, and 199mHg, the value E given in Publication 68 is 15-25 
times greater than the value HE from Publication 30 (Table 6.2).  As discussed in Section 3, there 
is evidence that the models of both ICRP Publication 30 and Publication 68 substantially 
overestimate retention of mercury vapor in the lungs.  Modeling of the behavior of mercury 
vapor within the structure of the updated respiratory model but with improved parameter values 
that are more consistent with the experimental data would yield substantially lower effective 
dose coefficients than those given in ICRP Publication 68 for most isotopes of mercury. 
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6.3.  Comparison of effective dose coefficients of ICRP Publication 30 
 with currently recommended values for members of the public 
 
 The dose coefficients of ICRP Publication 30 and Federal Guidance Report No. 11, 
particularly the effective dose coefficient, have been applied to members of the public as well as 
to workers.  While it is recognized by most investigators that dose per unit intake may often be 
greater for infants and children than for adults, it is considered that such difference with age may 
often be offset by lower usage (intake) of environmental media at younger ages. 
To compare effective dose coefficients for members of the public with coefficients given 
in ICRP Publication 30, the coefficients for members of the public were normalized to the 
expected usage of environmental media, as given in Federal Guidance Report No. 13 (EPA, 
1999).  That is, inhalation dose coefficients were adjusted to consider differences with age in air 
intake, and the ingestion dose coefficients were adjusted to consider differences with age in 
intake of food energy and water.  It is recognized that these adjustments may not be appropriate 
for consideration of specific cases.  For example, ingestion of radioiodine is often determined 
largely by intake of milk, which may not be closely related to intake of food energy or water for 
a given individual or group.  Similarly, intake of radiostrontium appears to be closely related to 
intake of calcium, whose age-specific pattern of intake may not be closely related to intake of 
food energy or water for a given individual or group. 
 Adjustment factors used to account for differences with age in air “usage” were 0.15, 
0.23, 0.40, 0.69, and 0.90 for ages 100 d, 1 y, 5 y, 10 y, and 15 y, respectively, based on average 
ventilation rates given in Federal Guidance Report No. 13 (EPA, 1999).  For ingestion, 
adjustment factors were based on consideration of differences with age in intake of both food 
energy and water.  Water intake was normalized to a value of 1.0 for the adult, whose intake was 
based on the average of values given in Federal Guidance Report No. 13 for ages 20-50 y.  A 
similar normalization was done for food intake, and the value for each age was taken as the 
average of the normalized values for food and water.  For ingestion ages 100 d, 1 y, 5 y, 10 y, 
15 y, and adulthood, this yielded normalized values of 0.17, 0.22, 0.48, 0.61, 0.78, and 1.0. 
Results are summarized in Table 6.4 for inhalation and Table 6.5 for ingestion. In these 
tables, the radionuclides are divided into cases in which the effective dose coefficients have been 
changed to roughly the same extent for generally the same reasons.  For each such grouping, the 
last column of the table indicates the main reasons for changes in the effective dose coefficients. 
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Table 6.4.  For inhalation, examples of usage-adjusted effective dose coefficients E for 
members of the public that differ substantially from the value HE of ICRP Publication 30. 
 
 
Radionuclides 
 
Type 
 
E(adjusted):HE 
 
 
Changes in ICRP models contributing most 
heavily to change in effective dose coefficient 
 
Sr-90, Cs-137, Pb-202, 
Pb-205, Pb-210 
 
F 
 
~0.1-0.2  
infants, young 
children 
 
New biokinetic and dosimetric models 
depicting faster turnover but lower tissue 
masses for children yield only moderate 
differences with age in inhalation doses.  
Lower intakes by infants, young children give 
lower adjusted values. 
 
Several short-lived 
radionuclides, such as 
Sb-128a, Ho-162, Hf-177m, 
Hf-182m, Ta-182m, Os-180 
 
M 
 
5-8  
Infants, young 
children 
 
Introduction of explicit weighting factors for 
stomach and/or colon. 
 
Bi-212, Bi-213, Bi-214, 
Th-226 
 
M 
 
5-10 
various ages 
 
High dose to ET region of lungs; introduction 
of splitting rule for Remainder; high weight 
given to dose to bronchial tissues. 
 
Ac-227, Th-229, Np-232, Np-
236a, Np-237 
 
M 
 
0.02-0.2 
all ages 
 
Reduced absorption to blood; reduced dose 
estimates for bone surface due to updated 
systemic biokinetic model, including treatment 
of decay chain members in some cases; 
reduced weighting factor for bone surface. 
 
Be-10, Mo-93, Pd-107, 
Pm-145, Lu-176, Ir-192m  
 
S 
 
0.1-0.2  
mainly infants and 
young children 
 
Lower deposition in deep lung due to changes 
in deposition model, default particle size.  Dose 
to deep lung main contributor to effective dose. 
 
Zr-93; Ac-227, Th-229, 
Th-230, Th-232, Pu-239, 
Pu-240, Pu-241, Pu-242, 
Pu-244, Cf-249, Cf-251 
 
S 
 
0.03-0.2 
all ages 
 
Reduced deposition in deep lungs; reduced 
absorption to blood; lower dose estimates for 
bone surface often given by updated systemic 
biokinetic models including new treatment of 
decay chain members in some cases; reduced 
eighting factor for bone surface.  w
  
Hg-193, Hg-193m, Hg-195, 
Hg-195m, Hg-197, Hg-197m, 
Hg-199m 
 
V 
 
5-25 
all ages 
Assignment of mercury vapor to bound 
compartments of respiratory tract, which are 
close to sensitive cells. 
 
 
 For ingestion as well as inhalation, numerous cases arise in which the usage-adjusted 
effective dose coefficient for members of the public differs substantially from the corresponding 
effective dose coefficient of ICRP Publication 30.  This is in contrast to the conclusions for 
occupational exposure, where the changes in ingestion dose coefficients are less extensive than 
those for inhalation dose coefficients.  The greater differences for environmental intakes are 
associated mainly with changes in f1 values, particularly the use of relatively high f1 values for 
infants and children. 
 85
 
 Table 6.5.  For ingestion, examples of usage-adjusted effective dose coefficients E for 
members of the public that differ substantially from the value HE of ICRP Publication 30. 
 
 
Radionuclides 
 
E(adjusted):
HE 
 
 
Changes in ICRP models contributing most heavily to 
change in effective dose coefficient 
 
C-11 
 
7-14 (all 
ages) 
 
Change from instantaneous distribution of C to allow 
residence in stomach; introduction of tissue weighting 
factor for stomach. 
 
Short-lived nuclides such as Cl-39, 
K-45, Co-60m, Ga-67, As-69, Se-81, 
Br-80, Rb-89, Y-95, Nb-88, Rh-107, 
In-112, Sb-120a, Cs-130, Te-133, 
Ba-131m, La-143, Pr-147, Sm-155, 
Lu-178, Ta-186, Pb-211, Bi-214, 
Am-244m, Cf-244 
 
3-4 (infants) 
 
Introduction of explicit weighting factors for stomach, 
colon; application of adult transit times to children in con-
junction with smaller organ masses for children. 
 
Ge-67, Ge-68, Ge-69, Ge-71, Ge-75, 
Ge-77 
 
3-8  (various 
ages) 
 
Introduction of explicit weighting factor for colon; explicit 
transfer of excreted Ge through intestines.  
 
Several isotopes of Tc and Re, 
including Tc-99 and Re-187 
 
3-5 (infants, 
young 
children) 
 
Introduction of explicit weighting factor for stomach 
(source organ for Tc and Re); age-invariant biokinetics in 
conjunction with age-specific organ masses. 
 
Fe-55, Fe-59, Fe-60 
 
3-8 (various 
pre-adult 
ages) 
 
Higher f1 values for Fe in infants and children; changes in 
systemic biokinetic model for Fe giving higher estimates 
of activity in red marrow and liver. 
 
Mo-93 
 
3-9 (all ages) 
 
Updated model for Mo has long-term retention in bone. 
 
I-120, I-123, I-124, I-126, I-128, I-130, 
I-131, I-132m, I-133, I-135 
 
3-4 (infants, 
young 
children) 
 
Smaller thyroid mass at young ages, with similar effective 
half-times at different ages for short-lived isotopes of 
iodine.  Increased tissue weighting factor for thyroid. 
 
Cs-134, Cs-137 
 
0.2-0.3 
(infants) 
 
 Difference with age in usage of food and water. 
 
Sm-146, Sm-147, Gd-148, Gd-152 
 
~5 (infant) 
 
Substantially higher f1 value assigned to infant. 
 
Po-210 
 
3-9 (various 
ages) 
 
Substantially higher f1 values for all ages.  Much different 
biokinetic model depicts high accumulation in some 
tissues with high weighting factors (e.g., red marrow). 
Highest ratios for young children stem from age-
independent biokinetics and smaller tissue masses. 
 
Ba-133, Ra-224, Ra-225, Ra-226, 
Ra-227, Ra-228 
 
3-13 (various 
ages) 
 
Higher f1 values assigned to children.  Substantially 
different biokinetic models.  High skeletal retention at 
some ages  Independent kinetics of Ra chain members. 
 
Several actinides, including Ac-227, 
Th-232, Pa-231, Np-236a, Np-237, 
Pu-236, Pu-238, Pu-239, Pu-240, 
Pu-241, Pu-242, Pu-244, Am-241, 
Am-242m, Am-243, Cm-243, 
Cm-244, Cm-245, Cm-246, Cm-247 
 
0.04-0.3 
(ages 1 y 
through 
adult) 
 
Decrease in f1 values.  Substantially different systemic 
biokinetic models for bone surface seekers depicting 
burial in bone volume, resulting in lower dose estimates 
for bone surface and red marrow.  Reduction of tissue 
weighting factor for bone surface. 
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